{
  "id": "hyperlipidemia",
  "title": "Hyperlipidemia",
  "lang": "en",
  "source_lang": "en",
  "summary": "Abnormally high blood lipid levels that raise the risk of atherosclerotic cardiovascular disease.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "Dyslipidemia",
    "Hyperlipoproteinemia"
  ],
  "generated_at": "2026-10-15",
  "model": "pro/claude-haiku-5-5",
  "url": "https://aiwiki.page/en/hyperlipidemia/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/hyperlipidemia/",
      "json": "https://aiwiki.page/zh/hyperlipidemia.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Hyperlipidemia is an abnormal elevation of lipids in the blood, most often cholesterol, triglycerides, or both, that reflects disturbed production, transport, or clearance of lipoprotein particles. The term is used interchangeably with the broader term dyslipidemia, which also covers low HDL cholesterol and other lipid abnormalities. Because lipid particles that carry cholesterol into artery walls drive atherosclerosis, hyperlipidemia is one of the most important modifiable risk factors for cardiovascular disease and stroke, and it contributes substantially to premature illness and death worldwide. It is usually silent, so it is identified through laboratory testing rather than symptoms.\n\nThis entry explains the biology behind the condition, including how lipids are packaged into lipoproteins and how the LDL receptor clears them from circulation. It then describes the classification schemes used to sort cases by cause (primary, genetic, and secondary) and by lipid pattern, and the principal inherited disorders such as familial hypercholesterolemia. The entry covers the clinical features and complications, the links to diabetes, obesity, hypothyroidism, and chronic kidney disease, and the diagnostic work-up and risk-estimation tools used in practice.\n\nThe second half addresses management: the lipid targets set by current guidelines, including the 2026 ACC/AHA update, drug classes such as statins, ezetimibe, and PCSK9 inhibitors, lifestyle measures, care for children and pregnant patients, and monitoring for adverse effects. The entry closes with epidemiology, the history of discovery, and unresolved questions in the field."
    },
    {
      "heading": "Definition and Terminology",
      "text": "Hyperlipidemia is the term for an excess of lipids circulating in the blood. In practice it is recognized from a lipid panel showing raised total cholesterol, raised LDL cholesterol, raised triglycerides, or a mixture of these. An elevated reading in the fasting state points to either faster production of lipoproteins or slower removal of them. The label therefore describes a laboratory pattern rather than one specific disorder, and the same pattern can arise from very different underlying mechanisms, from inherited gene variants to diet and medication effects. Its consequences are discussed in the sections on lipoprotein transport and atherosclerosis.\n\nThe related terms are used with different scopes. Dyslipidemia is the wider umbrella: it is the broader term for any unhealthy lipid pattern, including high LDL, high triglycerides, or low HDL. Hyperlipidemia is therefore a subset of dyslipidemia. Hypercholesterolemia is narrower still. Some usages restrict it to raised LDL cholesterol, while other authors include a low HDL level within it. This disagreement shows that the nomenclature is a convention rather than a fixed taxonomy.\n\nLipid cutoffs are partly conventional. Guideline committees choose the values that define abnormality from population distributions, outcome data, and evidence about treatment, and these values change over time. The 2026 ACC/AHA dyslipidemia guideline retires and replaces the 2018 guideline, and LDL-C and non-HDL-C treatment goals are back to guide lipid-lowering therapy. Its evaluation thresholds illustrate the point: persistently elevated non-fasting triglycerides of at least 175 mg/dL, fasting triglycerides of at least 150 mg/dL, and LDL-C persistently in the 160–189 mg/dL range prompt further assessment. Other bodies, including the European Society of Cardiology, use different cutoffs and goals, so a value that is flagged in one country may not be flagged in another.\n\nA lipid result is a laboratory finding and does not by itself establish a clinical disease. Clinical disease in the sense used here refers to the atherosclerotic events that elevated lipids promote. Hyperlipidemia usually produces no symptoms, and it does not always cause symptoms. Whether a value calls for treatment depends mainly on cardiovascular risk. Current guidance says management decisions should be based on overall cardiovascular risk, incorporating risk estimation, risk enhancers, and patient-specific factors, rather than lipid levels alone. Risk is commonly grouped by estimated 10-year probability of atherosclerotic cardiovascular disease, with high risk at 10% or more, and borderline (3–5%) or intermediate (5–10%) risk defining the other tiers. The same LDL value may therefore lead to different decisions for two people with different risk profiles.\n\nTerminology also varies across communities and eras. The 2018 US guideline addressed blood cholesterol, whereas the 2026 guideline makes dyslipidemia its organizing concept, which reflects a shift toward the broader term in North American cardiology. Veterinary medicine has its own convention, in which clinicians typically use the term hypercholesterolemia when there is an increase in serum cholesterol without lipemia, and hyperlipidemia when there is an increase in triglycerides and gross lipemia. British and European writing often uses the spelling \"hyperlipidaemia\" and \"dyslipidaemia.\" Because these usages differ, the same word can carry different meanings depending on the clinical field, the country, and the year of the source."
    },
    {
      "heading": "Lipids and Lipoprotein Transport",
      "text": "Lipoprotein particles as transport vehicles\n\nCholesterol and triglycerides are nonpolar and do not dissolve in plasma, so they circulate inside lipoprotein particles. Each particle has a hydrophobic core of cholesteryl esters and triglycerides, surrounded by a single layer of phospholipids, unesterified cholesterol, and apolipoproteins. Particles are classified by density, which rises as the triglyceride fraction falls and the protein fraction rises. Chylomicrons are the largest and least dense, at roughly 75 to over 1,000 nm in diameter. Very-low-density lipoprotein (VLDL) measures about 30 to 80 nm, low-density lipoprotein (LDL) about 18 to 25 nm, and high-density lipoprotein (HDL) about 5 to 12 nm. Intermediate-density lipoprotein (IDL) is a transitional particle formed during VLDL catabolism.\n\nApolipoproteins\n\nApolipoproteins provide structure and act as ligands or enzyme cofactors. ApoB-100, a protein of about 4,500 amino acids, is the single structural protein of VLDL, IDL, and LDL, with one copy per particle; because of this, apoB counts atherogenic particles. Chylomicrons and their remnants carry apoB-48, a shortened form generated in the intestine by mRNA editing. ApoA-I is the principal protein of HDL and activates lecithin–cholesterol acyltransferase (LCAT). ApoC-II activates lipoprotein lipase (LPL), and apoE mediates uptake of remnant particles by the liver.\n\nExogenous and endogenous pathways\n\nThe exogenous pathway carries dietary lipid. Bile salts emulsify fats in the intestine, and pancreatic lipase hydrolyzes triglycerides to monoglycerides and free fatty acids. Enterocytes re-esterify these into triglycerides and assemble chylomicrons with apoB-48. Chylomicrons enter the lymphatic system and reach the bloodstream through the thoracic duct. In capillaries of muscle and adipose tissue, LPL hydrolyzes their triglycerides, shrinking the particles into remnants that are cleared by the liver.\n\nThe endogenous pathway begins in the liver, which assembles VLDL from apoB-100, triglycerides, cholesterol, and phospholipids, with microsomal triglyceride transfer protein supplying lipid to the nascent particle. LPL acting on circulating VLDL produces IDL. Hepatic lipase and further lipolysis convert about half of IDL back to the liver for uptake, while the remainder becomes LDL. LDL, which carries most of the cholesterol in plasma, is cleared mainly by the liver through LDL receptors.\n\nReverse cholesterol transport\n\nReverse cholesterol transport is the proposed route by which peripheral cells export cholesterol to HDL for return to the liver. Lipid-poor apoA-I, secreted by the liver and intestine, takes up phospholipid and cholesterol through the transporter ABCA1, forming discoidal nascent HDL. LCAT esterifies the cholesterol, producing mature spherical HDL. Cholesteryl esters are then taken up by the liver through scavenger receptor class B type I (SR-BI) or transferred to apoB-containing particles by cholesteryl ester transfer protein (CETP).\n\nIts relationship to cardiovascular risk is debated. Low HDL cholesterol is consistently associated with coronary disease in epidemiological studies, but raising HDL cholesterol has not reliably reduced events. The CETP inhibitor torcetrapib raised HDL cholesterol yet increased cardiovascular events and mortality in its phase 3 trial, while anacetrapib modestly reduced major coronary events, an effect largely attributed to LDL lowering. Genetic studies have also not consistently shown that higher HDL cholesterol itself is causal. As a result, attention has shifted toward HDL function, such as cholesterol efflux capacity, rather than the cholesterol content of HDL alone."
    },
    {
      "heading": "Metabolic Mechanisms of Lipid Disturbance",
      "text": "Plasma lipid levels reflect a balance between how much lipoprotein the liver and intestine secrete and how quickly lipoproteins are removed from the circulation. Hyperlipidemia arises when that balance tips. Overproduction of apolipoprotein B-containing particles and impaired clearance of those particles produce different lipid patterns, and the regulation of hepatic cholesterol synthesis and receptor-mediated uptake determines how much LDL cholesterol the blood carries.\n\nOverproduction versus impaired removal\n\nIn the fasting state, the liver secretes very-low-density lipoprotein (VLDL), which is assembled from triglyceride, cholesterol esters and apoB-100. Insulin normally restrains this process by promoting degradation of apoB and limiting its synthesis. In insulin resistance, that restraint weakens. Forkhead box O1 (FoxO1) remains active in the nucleus, which raises expression of microsomal triglyceride transfer protein and apolipoprotein C-III. The result is secretion of large, triglyceride-rich VLDL1 particles, a pattern common in obesity and type 2 diabetes. Because VLDL exchanges lipids with HDL and LDL, excess VLDL output tends to lower HDL cholesterol and generate small, dense LDL particles.\n\nImpaired removal produces a related but distinct pattern. Triglyceride-rich particles are cleared by lipoprotein lipase at the capillary endothelium of muscle and adipose tissue, and their remnants are then taken up by hepatic receptors. When lipolysis is slowed, circulating VLDL accumulates even if hepatic secretion is normal. Clinical samples often show both defects together, so the two mechanisms are better understood as ends of a spectrum than as mutually exclusive categories.\n\nHepatic cholesterol synthesis and feedback control\n\nCholesterol is made in the endoplasmic reticulum through the mevalonate pathway, and HMG-CoA reductase catalyzes the rate-limiting step. The enzyme is controlled by two feedback systems. When sterol levels are high, the enzyme is degraded more rapidly and its synthesis slows; when sterol levels are low, both processes shift in the opposite direction.\n\nThe transcriptional arm of this control depends on sterol regulatory element-binding proteins (SREBPs), membrane-anchored transcription factors identified by Michael Brown and Joseph Goldstein. In sterol-replete cells, SREBP is retained in the endoplasmic reticulum by SCAP, a sterol-sensing chaperone. When sterols fall, SCAP carries SREBP to the Golgi, where it is proteolytically cleaved. The released fragment enters the nucleus and activates genes containing sterol regulatory elements, including those for HMG-CoA reductase and the gene for the LDL receptor. SREBP-2 is the isoform chiefly responsible for cholesterol biosynthesis in the liver, whereas SREBP-1c mainly drives fatty acid synthesis. SREBP-2 also activates PCSK9, a protein that promotes degradation of the LDL receptor, which means the same pathway that increases clearance can partly restrain it.\n\nThis feedback explains the action of statins. Inhibiting HMG-CoA reductase lowers intracellular cholesterol, which activates SREBP-2 and increases LDL receptor expression, but the compensatory rise in enzyme levels limits the reduction in cholesterol synthesis.\n\nThe LDL receptor and LDL clearance\n\nMost circulating LDL is removed by receptor-mediated endocytosis. The LDL receptor binds the apoB-100 on the LDL particle, and the complex is internalized through clathrin-coated pits. In lysosomes, the cholesterol esters are hydrolyzed, and the receptor is recycled to the cell surface. The liver accounts for the majority of this clearance.\n\nWhen receptor number or function falls, LDL remains in plasma for longer, and plasma LDL cholesterol rises. Heterozygous genetic receptor defects, which halve receptor activity, produce the common form of familial hypercholesterolemia, whereas homozygous loss causes severe elevations. Receptor activity can also be reduced by variants that increase PCSK9 activity, by apoB variants that bind the receptor poorly, and by increased PCSK9 levels in the circulation.\n\nLipoprotein lipase, hepatic lipase and related regulators\n\nLipoprotein lipase (LPL) hydrolyzes triglycerides in chylomicrons and VLDL, releasing free fatty acids that are taken up by tissues. Its activity is controlled by apolipoproteins such as apoC-II, which activates it, and apoC-III, which inhibits it. Hepatic lipase, located on the sinusoidal surface of the liver, acts on intermediate-density lipoprotein (IDL) and on the larger HDL subclass, helping convert IDL to LDL and remodeling HDL. Endothelial lipase acts mainly on HDL phospholipids.\n\nThese enzymes are themselves regulated. ANGPTL3, a protein secreted almost exclusively by hepatocytes, inhibits LPL and endothelial lipase, and its loss in humans is associated with lower triglyceride, LDL and HDL levels. Related proteins ANGPTL4 and ANGPTL8 also modulate LPL activity, and the interplay among these regulators is an active area of study. Because LPL and hepatic lipase govern how triglyceride-rich particles are cleared, variation in their activity shapes the triglyceride component of hyperlipidemia, while the LDL receptor and SREBP-controlled pathways shape its LDL component.\n\nFor disorders arising from these mechanisms, see classification by cause and primary genetic disorders."
    },
    {
      "heading": "Classification by Cause",
      "text": "Hyperlipidemia is most often sorted by its origin into primary and secondary forms. In broad terms, primary forms are the ones caused by specific genetic abnormalities, while secondary forms result from another disorder that alters plasma lipid and lipoprotein metabolism. Both categories share a common mechanism, since the body either makes too many lipids or cannot clear them effectively from the bloodstream. The categories describe the trigger, not a different biochemistry.\n\nHow the distinction is made in practice\n\nIn clinical work the label is assigned by exclusion. Clinicians first look for acquired contributors, and secondary causes should be excluded before primary hyperlipidemia may be diagnosed. A typical evaluation of a patient with raised lipids therefore includes liver function, urinary protein, creatinine, thyroid hormone levels and fasting blood glucose. Clues that point toward an inherited cause include a family history, since primary hyperlipidemia tends to run in families, and an onset early in life, because these disorders can produce significantly elevated lipid levels beginning in childhood or adolescence.\n\nSecondary causes fall into several groups. Endocrine disorders such as hypothyroidism and diabetes mellitus (including type 2 diabetes) are common examples, as are renal conditions such as chronic kidney disease and nephrotic syndrome. Excess body weight, particularly abdominal fat, is linked to elevated triglycerides, as is heavy alcohol intake. Many drugs also contribute, including certain diuretics, glucocorticoids, androgens and antiretroviral agents. Lifestyle factors such as physical inactivity and diets high in saturated fat or refined carbohydrates add to the list. The mechanisms behind these secondary patterns are described in a separate section.\n\nEstimates of the secondary share differ between sources. One review cited in a clinical overview suggests that about 30% to 40% of all hyperlipidemia is the secondary type, whereas a pharmacology reference states that primary hyperlipidemia caused by environmental and genetic factors is by far the most frequent, accounting for 98% of all cases. The discrepancy likely reflects differences in how the two categories were defined and in the populations studied.\n\nMultifactorial hyperlipidemia\n\nThe primary category is not uniformly monogenic. Primary hyperlipidemia may be caused by a single gene defect or, more commonly, by a polygenic background influenced by environmental factors. Most primary cases are therefore best understood as genetic factors interacting with environmental factors, with single-gene disorders representing a minority. Environmental exposures such as obesity, diabetes and excess alcohol are described as acting on a genetic background to produce hyperlipidemia.\n\nGenetic susceptibility of this kind is most clearly seen in familial combined hyperlipidemia (FCHL). Its pattern was first described in 1973, when it was initially described as an autosomal dominant inherited lipid disorder, but later studies showed a multigenic mode and complex inheritance. A genome-wide association study identified 175 single-nucleotide variants linked to the phenotype, and the disorder is judged to be at least 5x more common than familial hypercholesterolemia while carrying a similar coronary risk. In the polygenic model, many common alleles of small effect, rather than one large-effect mutation, accumulate and raise lipid levels.\n\nIdiopathic primary hypercholesterolemia\n\nSome patients have raised lipids for which no cause can be identified. Hyperlipidemia may be idiopathic, that is, without a known cause. In the cholesterol-specific form, this label is applied after secondary causes have been excluded and no causal variant has been found. Genetic testing does not close this gap. Familial hypercholesterolemia is classically linked to the LDL receptor pathway, yet only 40% of patients diagnosed with familial hypercholesterolemia are found to have a mutation in genes, so a substantial share of severe cases remain unexplained at the level of a single gene. Such cases are often grouped as polygenic or idiopathic, and the boundary between these groups is not sharp.\n\nGenetic and primary: a distinction of scope\n\nBecause a primary diagnosis can rest on a family pattern alone, the terms are not interchangeable. Most cases of primary hyperlipidaemia are due to genetic factors interacting with environmental factors, which means that a primary label does not always imply a single identifiable gene. The relationship is asymmetric: every genetic form is primary, but a primary form may lack a demonstrable genetic cause. This is why the classification by cause is a working framework rather than a settled taxonomy, and why later sections on genotype and phenotype address the overlap in more detail."
    },
    {
      "heading": "Classification by Lipid Pattern and the Fredrickson System",
      "text": "The five phenotypes\n\nDonald Fredrickson, working with Robert Levy and Robert Lees, classified hyperlipidemias by which lipoprotein class was raised. Paper electrophoresis of lipoprotein was added to measurement of serum cholesterol and triglycerides, and he described five types of hyperlipoproteinaemias, Types I to V. Type II was later (1970) subdivided into IIa and IIb, the latter accompanied by raised triglycerides, and familial combined hyperlipidaemia was defined in 1972. Some tabulations count six categories by treating IIa and IIb separately, so the number reported varies between sources.\n\n- Type I is driven by chylomicron accumulation. Its common causes are lipoprotein lipase deficiency and defects in apoC-II, a cofactor of the enzyme, while chylomicron clearance is impaired. Type I patients are usually identified by early onset as youth of hypertriglyceridemia and pancreatitis. The condition is rare, with a prevalence of about 1 in 1,000,000 in the general population, and patients respond minimally, or not at all, to TG-lowering drugs, so dietary fat is restricted to about 20 g per day.\n- Type IIa is an isolated LDL elevation. Its familial form arises from mutations in the LDL receptor gene or the APOB gene, and the familial form is characterized by tendon xanthoma, xanthelasma and premature cardiovascular disease. Non-genetic forms also occur, which is why the phenotype cannot be read as a diagnosis on its own.\n- Type IIb combines raised LDL with raised VLDL. It is the phenotype most closely linked to familial combined hyperlipidemia, which is characterized by increased LDL and triglyceride concentrations, and often accompanied by decreased HDL.\n- Type III (dysbetalipoproteinemia) reflects accumulation of cholesterol-rich remnant particles, mainly IDL. The impaired clearance is due to a defect in apolipoprotein E (apoE). Its clinical features include xanthomatosis and premature coronary and/or peripheral vascular disease. It was the first of these phenotypes recognized as a distinct entity separate from familial hypercholesterolemia.\n- Type IV is a VLDL elevation with normal or mildly raised cholesterol. It is associated with familial hypertriglyceridemia, which is an autosomal dominant condition occurring in approximately 1% of the population. Sporadic hypertriglyceridemia and diabetes can also produce this pattern.\n- Type V combines chylomicrons and VLDL, and is often linked to diabetes and to episodes of pancreatitis.\n\nIn a large clinical laboratory sample analyzed for these patterns, the prevalence of the FLL phenotypes was 40%: Type I (0.02%), Type IIa (3.9%), Type IIb (10.4%), Type III (1.7%), Type IV (24.2%), and Type V (0.13%).\n\nAdoption by the WHO and the decline of routine use\n\nThe scheme spread widely because it offered a standardized vocabulary. It was adopted by the World Health Organization as an international standard in 1972, and thus brought global attention to lipoprotein and lipid disorders. Its original laboratory basis was demanding. The classification was originally established by separating lipoproteins by density gradient ultracentrifugation, but later it was mostly performed by the more convenient method of agarose gel electrophoresis.\n\nOver time, its clinical weaknesses became clearer. It describes what is elevated but not why, and it omits HDL. Fredrickson's classification is based simply on biochemical parameters, and does not represent actual diagnoses or address the source of dyslipidemia as primary or secondary. Because it was devised before HDL was recognized as a prognostic marker, the classification was devised before the importance of HDL as a prognostic indicator was recognised. It also cannot characterize dyslipidemias related to low HDL-C or elevated Lp(a). Practical testing favors cheaper assays, and the phenotyping is currently only available in specialty centers and is no longer widely used in clinical practice. Today it is still used for didactic purposes.\n\nEfforts to keep the logic while simplifying the method have followed. In 2007, Sniderman and colleagues used apolipoprotein B, alongside total cholesterol and triglycerides, as surrogate measures of lipoprotein concentration. This approach identifies the common apoB-containing phenotypes but cannot identify Type III.\n\nModern categorization\n\nCurrent practice sorts disorders by the lipid species that are abnormal rather than by pattern number. The main categories are isolated hypercholesterolemia, combined hyperlipidemia, isolated hypertriglyceridemia, and low HDL. These are further sorted by whether a genetic or pathological cause has been found. Guidelines still set treatment largely according to individual lipoproteins such as LDL rather than combinations. Treatment recommendations in clinical practice guidelines are currently based on levels of individual lipoproteins, such as LDL, and not lipoprotein combinations.\n\nLimits of phenotype-based classification\n\nA phenotype is not a genotype. A single genetic defect (genotype) can result in several different phenotypes. On the other hand, a particular phenotype can be caused by different genetic defects. The type III pattern illustrates this: it is strongly associated with APOE2 homozygosity, yet expression of the type III pattern in patients with APOE2 homozygosity is modified by mutations in other lipid-related genes and likely requires comorbid disease or exposure. Type IIb is considered polygenic, and Fredrickson hyperlipoproteinemia phenotypes are predominantly polygenic, with no simple, accurate, and reproducible way to directly characterize them.\n\nSeverity also varies within a single pattern. Phenotypes derived from specialty clinics may over-represent extreme cases. These settings may tend to capture extreme phenotypes, and conclusions drawn may not generalize to contemporary general populations beset with growing obesity and diabetes epidemics. Modern population analyses using apoB-based algorithms have found that the patterns are more common than the older clinical picture suggested. In one study, those with diabetes (51.6%) or obese BMI (49.0%) had higher prevalence of FLL phenotypes compared to those without diabetes (31.3%; p < 0.001) and normal BMI (18.3%; p < 0.001). Whether phenotype labels add value beyond conventional lipid measures for treatment decisions remains uncertain."
    },
    {
      "heading": "Primary Genetic Disorders",
      "text": "Primary hyperlipidemias with a monogenic or oligogenic basis are the subset of lipid disorders in which one inherited defect, or a small number of defects, produces a recognizable lipid profile. Many are detected in childhood or early adulthood, so family history is central to recognizing them.\n\nFamilial hypercholesterolemia\n\nFamilial hypercholesterolemia (FH) is the best-characterized monogenic disorder of LDL metabolism. Most cases follow an autosomal dominant pattern, so a child of an affected heterozygous parent has a 50% chance of inheriting the variant. Variants in LDLR, which encodes the LDL receptor, account for the large majority of genetically confirmed cases. Variants in APOB, which encodes apolipoprotein B-100 (the ligand the receptor recognizes), account for a smaller share, and gain-of-function variants in PCSK9, which accelerate receptor degradation, are rarer still. Variants in LDLRAP1, an adaptor needed for receptor internalization, cause a recessive form discussed below. Genetic testing does not explain every clinical case: a causative variant is found in only about 40% of patients with a clinical diagnosis, and the remainder are thought to reflect polygenic inheritance, in which many common LDL-raising variants accumulate.\n\nHeterozygous FH, with one defective allele, typically raises LDL cholesterol two- to threefold above normal. Without treatment it is associated with coronary disease in middle age, and it is among the more common single-gene disorders, with a prevalence of about 1 in 220 in large genetic studies. Homozygous FH, with two defective alleles, produces a much more severe phenotype, with LDL cholesterol several-fold above normal and a risk of coronary events in childhood or adolescence if untreated.\n\nFamilial combined hyperlipidemia\n\nFamilial combined hyperlipidemia (FCHL) is generally regarded as the most common inherited lipid disorder. Its estimated prevalence ranges from roughly 1 in 200 to about 1 in 100 depending on the population and the diagnostic criteria used. Affected individuals show elevations of LDL cholesterol, VLDL, triglycerides, or apolipoprotein B, and the pattern can differ between relatives in the same family and even within one person over time. Isolated apoB elevation with a near-normal standard lipid panel can also occur. Early descriptions in 1973 treated FCHL as a single dominant trait, but later pedigree and genetic work showed a complex, polygenic inheritance with variable penetrance. A locus on chromosome 1q21–q23 has been linked to the condition, but its causal genes remain incompletely identified. Because plasma LDL cholesterol is usually lower than in FH, the risk of premature atherosclerosis is nonetheless comparable to that of FH.\n\nFamilial hypertriglyceridemia, familial chylomicronemia, and familial dysbetalipoproteinemia\n\nFamilial hypertriglyceridemia is an inherited elevation of VLDL triglycerides, typically polygenic and modified by metabolic factors such as obesity and insulin resistance. Familial chylomicronemia syndrome, a severe form, produces very high fasting triglycerides through accumulation of chylomicrons. It results from defects in the lipoprotein lipase pathway, most often in LPL itself, and less frequently in APOC2, APOA5, GPIHBP1, or LMF1. The marked triglyceride elevation carries a risk of acute pancreatitis, which usually appears in childhood or adolescence in the classic form.\n\nFamilial dysbetalipoproteinemia (type III hyperlipoproteinemia) is caused mainly by homozygosity for the APOE2 allele, a variant that carries a cysteine substitution for arginine. The E2 isoform binds the LDL receptor only weakly, so cholesterol-rich remnant particles of VLDL and chylomicrons accumulate in plasma. Patients have elevated cholesterol and triglycerides, often with relatively modest LDL cholesterol, and roughly half develop cutaneous xanthomas. Palmar crease xanthomas, yellowish planar deposits in the skin creases of the hands, are considered characteristic of the disorder, which is also associated with several-fold higher rates of premature coronary and peripheral arterial disease. Xanthomas in other sites, such as tuberoeruptive lesions over the elbows and knees, are also common.\n\nRarer recessive and single-gene forms\n\nAutosomal recessive hypercholesterolemia (ARH) results from biallelic variants in LDLRAP1. Its lipid pattern resembles that of homozygous FH, but heterozygous carriers are usually unaffected. Sitosterolemia, another recessive disorder, arises from variants in ABCG5 or ABCG8, which normally limit the intestinal absorption and promote the biliary excretion of plant sterols and cholesterol. Affected individuals absorb excess sterols, leading to elevated plasma plant sterols, raised LDL cholesterol, and premature atherosclerosis; the condition responds well to sterol-absorption inhibitors such as ezetimibe. Lysosomal acid lipase deficiency, caused by recessive variants in LIPA, impairs the breakdown of cholesteryl esters and triglycerides within lysosomes. The infantile form, Wolman disease, is severe, whereas the later-onset form, cholesteryl ester storage disease, presents with hepatomegaly and a dyslipidemia that resembles FH or mixed hyperlipidemia.\n\nElevated lipoprotein(a)\n\nElevated lipoprotein(a) is a heritable risk factor with its own genetic basis, distinct from the single-gene disorders above. Lipoprotein(a) consists of an LDL-like particle with apolipoprotein B-100 covalently bound to apolipoprotein(a), encoded by the LPA gene on chromosome 6q25. The number of kringle IV repeats in apo(a) varies between individuals, and smaller isoforms, carrying fewer repeats, are generally associated with higher plasma concentrations. Plasma levels are therefore largely determined by genotype and differ widely among individuals and ethnic groups, with only modest responsiveness to diet or exercise. Because of this genetic control, a single measurement can classify a person as having a lifelong elevated level."
    },
    {
      "heading": "Secondary and Acquired Causes",
      "text": "Secondary hyperlipidemia is the form in which an existing condition, a drug, or an exposure produces the lipid abnormality, rather than an inherited defect alone. Clinicians are expected to look for these contributors before attributing a lipid pattern to a primary disorder. During the work-up for hyperlipidaemia, excluding secondary causes is one of the essential steps, and these include endocrine diseases, diabetes, drugs, nephrotic syndrome, and pregnancy. The pattern each cause produces differs, so the lipid panel itself often points toward a likely source.\n\nEndocrine and metabolic contributors\n\nDiabetes is the clearest example of a metabolic cause. Lipoprotein lipase needs insulin for full activity, so the pathway is affected by genetic disorders of type 1 and type 2 diabetes. In type 2 diabetes and obesity, the combination may be a consequence of obesity, poor control of diabetes, or both, which may increase circulating free fatty acids, leading to increased hepatic very-low-density lipoprotein production. The resulting triglyceride-rich particles then exchange lipids with LDL and HDL, which favors small, dense LDL. In general, diabetes tends to raise triglycerides more than cholesterol.\n\nHypothyroidism pushes LDL cholesterol upward and also raises triglycerides to a lesser degree. In individuals who carry a homozygous apoE2 genotype, untreated hypothyroidism can unmask dysbetalipoproteinemia, illustrating the \"second hit\" concept in which a secondary factor must be present for a primary susceptibility to produce disease. Insulin resistance belongs to the same metabolic cluster, alongside obesity and impaired glucose tolerance, which together form the basis of the metabolic syndrome.\n\nRenal and hepatic contributors\n\nNephrotic syndrome is among the strongest secondary drivers. It is thought to increase hepatic synthesis of VLDL and may also slow the catabolism of both LDL and VLDL. Cholesterol typically rises markedly, with a smaller increase in triglycerides. Chronic kidney disease, by contrast, is more often associated with elevated triglycerides, since CKD can disrupt normal lipid metabolism in multiple ways. Reduced kidney function is therefore a contributor to the residual cardiovascular risk that persists even after LDL is controlled.\n\nCholestatic and obstructive liver disease impairs the liver's handling of cholesterol, which leads to its accumulation in the blood. Biliary obstruction characteristically raises cholesterol, with a variable effect on triglycerides.\n\nObesity, inactivity, diet, and alcohol\n\nLifestyle factors interact closely with genetic susceptibility. In most patients, hyperlipidemia has a polygenic inheritance pattern, and its manifestations are largely influenced by secondary factors such as central obesity, saturated fat intake, and dietary cholesterol. A sedentary lifestyle and advancing age also appear among the frequent contributors to raised cholesterol or triglycerides. Dietary effects differ by nutrient: a diet high in simple carbohydrates such as added sugars and refined grains can raise blood triglycerides, while excess saturated or trans fat can increase LDL cholesterol. Excessive alcohol consumption can raise both triglycerides and LDL.\n\nMedications and other exposures\n\nMany drugs alter lipid levels as an unintended effect. Frequently implicated agents include thiazide diuretics, beta-blockers, estrogen-progestin contraceptives, and antiretrovirals. A review of commonly prescribed drugs found that diuretics, β-blocking agents, progestogens, combined oral contraceptives containing second-generation progestogens, danazol, immunosuppressive agents, protease inhibitors, and enzyme-inducing anticonvulsants tend to worsen the lipid profile, whereas other agents, including estrogens and selective estrogen receptor modulators, mostly improve it. Immunosuppressants such as cyclosporine and tacrolimus are also listed among causes of secondary dyslipidemia.\n\nThe effect is not uniform across drug classes. Some drugs, for example, isotretinoin, acitretin and antipsychotics, mainly elevate triglyceride levels. Thiazide-associated LDL increases are modest and are known to be short-term. Some drug-induced triglyceride elevations are clinically important because several cases of pancreatitis attributable to drug-induced hypertriglyceridaemia have been reported. Where feasible, management generally favors replacing the offending agent with an equivalent alternative, although such alternatives are often difficult to find. Recognizing a drug effect therefore changes both the diagnosis and the treatment plan."
    },
    {
      "heading": "Clinical Features and Complications",
      "text": "Silent presentation and cutaneous signs\n\nHyperlipidemia itself rarely produces symptoms. Most people learn of it through a routine lipid panel, and the lipid abnormality is usually discovered long before any clinical event. Some patients, however, show visible deposits of lipid in the skin, eyes, or tendons, which are collectively called xanthomas (lipid-laden deposits that form when lipoproteins accumulate in tissue, where macrophages become lipid-filled foam cells). Their appearance depends on the underlying lipid abnormality.\n\nThe most common type is xanthelasma palpebrarum, which appears as soft, flat, yellowish plaques near the inner corner of the upper eyelids. These lesions are usually painless and are frequently seen in people whose lipid levels are only moderately raised, so their presence is a weak diagnostic clue on its own. Tendon xanthomas, by contrast, are firm nodules over the Achilles tendon, the knuckles, and the extensor tendons of the hands. They are strongly associated with heterozygous and homozygous familial hypercholesterolemia and are uncommon in children with mild dyslipidemia. Eruptive xanthomas are crops of small yellow papules on the extensor surfaces of the limbs, buttocks, and trunk. They reflect severe hypertriglyceridemia, often in association with poorly controlled diabetes, obesity, or excess alcohol, and they typically regress once triglyceride levels fall.\n\nCorneal arcus is a grayish-white ring at the edge of the cornea. It is common in older adults and is not specific to lipid disorders. When it appears before about age 45, however, it raises suspicion of familial hypercholesterolemia, and in a child it is a more significant sign. The combination of tendon xanthomas and early corneal arcus is particularly strong evidence for a monogenic disorder.\n\nAcute pancreatitis and triglyceride thresholds\n\nAcute pancreatitis is the most serious acute complication of hyperlipidemia. It is caused by very high triglyceride concentrations, which are believed to act through the release of free fatty acids from triglyceride-rich particles within the pancreatic microcirculation. Patients typically present with sudden, severe epigastric pain, often accompanied by vomiting, and the condition can progress to organ failure.\n\nThe risk rises with triglyceride concentration, but no single cutoff is accepted by all bodies. Severe hypertriglyceridemia is generally defined as 500 mg/dL or more, and it affects roughly 1% of adults. Above 1000 mg/dL is the level most often cited as a risk threshold, and the European Society of Cardiology and European Atherosclerosis Society set the cut point at 885 mg/dL (10 mmol/L). Absolute risk is nevertheless modest: approximately 5% of people with triglycerides above 1000 mg/dL develop pancreatitis, rising to around 10–20% at levels above 2000 mg/dL. Extreme hypertriglyceridemia, at or above roughly 880 mg/dL, is associated with a particularly high rate of events. In a large general-population cohort, nonfasting triglycerides of 177 mg/dL or more were linked to a meaningful increase in pancreatitis risk, which indicates that the threshold for concern is not confined to the highest values.\n\nPancreatitis is also a marker of a more serious disorder. Recurrent episodes are common when the underlying triglyceride elevation is not corrected, and a substantial proportion of patients with severe hypertriglyceridemia and an episode of pancreatitis go on to develop type 2 diabetes within several years. Chylomicronemia syndrome, a rare condition with markedly elevated chylomicrons, can produce recurrent abdominal pain, pancreatitis, eruptive xanthomas, and enlargement of the liver or spleen.\n\nAdvanced familial disease in childhood\n\nFamilial hypercholesterolemia is the clearest example of hyperlipidemia that manifests early. Heterozygous carriers usually have a lifelong, moderately raised LDL cholesterol and tend to become symptomatic in middle age, often through premature coronary artery disease. Homozygous carriers have LDL levels far higher than heterozygotes and can show signs in early childhood. Clinical reports describe children with tendon or cutaneous xanthomas, corneal arcus, and LDL concentrations several times the upper reference limit, in some cases with lipid abnormalities detectable as early as the first years of life. Aortic valve involvement and coronary events may occur in young adults, and untreated homozygous patients face a very high risk of early atherosclerotic death. Where genetic testing is unavailable, clinicians rely on the physical examination and lipid levels, as well as family history, to make the diagnosis.\n\nRecognition through consequences\n\nFor most patients, the first recognized consequence of hyperlipidemia is cardiovascular. Atherosclerosis narrows the coronary arteries, which can produce exertional chest pain (angina) or a myocardial infarction. Involvement of cerebral arteries may cause ischemic stroke or transient ischemic attack, and narrowing of the leg arteries leads to intermittent claudication, pain on walking that eases with rest. Peripheral arterial disease is often recognized in the clinic through reduced pulses or non-healing wounds. These events are frequently the reason a lipid profile is ordered, and they usually reflect years of accumulated LDL exposure rather than a single abnormal value. Recognition of hyperlipidemia through these consequences therefore depends on linking an event to a lipid profile and a family history, which is why physicians are encouraged to examine the skin, eyes, and tendons during routine assessment."
    },
    {
      "heading": "Atherosclerosis and Cardiovascular Risk",
      "text": "Retention of apoB-containing particles in the intima\n\nAtherosclerosis begins when apolipoprotein B-containing particles, mainly LDL, triglyceride-rich remnants, and lipoprotein(a), enter the arterial intima, the innermost layer of the vessel wall. Their entry depends on how many particles circulate and on endothelial permeability, which is raised by hypertension, smoking, and diabetes. Once in the intima, these particles bind to proteoglycans in the extracellular matrix. This retention keeps them in the wall far longer than they would stay in plasma. Retained LDL is then chemically modified, most importantly by oxidation, and modified particles act as the main trigger of a local inflammatory response. Endothelial cells respond by expressing adhesion molecules such as VCAM-1 and releasing chemokines such as MCP-1, which recruit circulating monocytes. Those monocytes become macrophages that take up modified lipoprotein through scavenger receptors. Because these receptors are not shut off by cellular cholesterol levels, the macrophages accumulate lipid and become foam cells.\n\nFrom fatty streak to plaque and thrombosis\n\nFoam cells gather into fatty streaks, flat lesions that autopsy studies have found in the aortas of children and adolescents. Fatty streaks alone rarely cause symptoms, but over years they can evolve. Smooth muscle cells migrate from the media into the intima, proliferate, and secrete collagen and other matrix components. The result is a fibrous plaque with a fibrous cap over a lipid-rich core containing dead foam cells and cholesterol crystals. Plaques with thin caps and large necrotic cores are the most vulnerable. When such a plaque ruptures, or when its surface erodes, thrombogenic material such as tissue factor is exposed to blood. Platelets adhere and a clot forms. If the thrombus blocks a coronary artery, the result is a cardiovascular event, namely myocardial infarction; if it occurs in a carotid or cerebral artery, it causes an ischemic stroke. Many acute events arise from plaques that had caused only moderate narrowing beforehand, which is one reason the degree of luminal narrowing is an imperfect predictor of events.\n\nCumulative exposure and the evidence on LDL\n\nThe strongest evidence that lowering LDL reduces events comes from randomized trials of statins. A meta-analysis by the Cholesterol Treatment Trialists' Collaboration found that each reduction of 1 mmol/L (about 39 mg/dL) in LDL cholesterol was associated with a proportional reduction of roughly one fifth in major vascular events. Absolute benefit is larger when baseline risk is higher, so the same relative reduction matters most in people with the most accumulated disease. Genetic studies support a related principle. People who carry variants that lower LDL from birth tend to have fewer coronary events across their lives, which suggests that the total amount of LDL exposure accumulated over decades, rather than a single measurement, drives the risk. This concept of cumulative exposure explains why early and sustained reduction is considered more beneficial than late intervention.\n\nResidual risk\n\nMany events occur even when LDL is well controlled, and attention has turned to other contributors. Lipoprotein(a) is determined largely by genetics, and about one in five people has elevated levels. It consists of an LDL-like particle with apolipoprotein(a) attached, and it appears to be both pro-atherogenic and pro-thrombotic. Triglyceride-rich remnants, including remnant cholesterol from partly cleared chylomicrons and VLDL, can penetrate the intima, and genetic analyses associate higher remnant cholesterol with greater risk. Inflammation is a third contributor. The JUPITER trial found that statin therapy reduced events in people with normal LDL but elevated high-sensitivity C-reactive protein. The CANTOS trial showed that an interleukin-1β inhibitor lowered recurrent events in people with prior myocardial infarction and raised CRP, without lowering LDL, though it also increased fatal infections. The relative importance of these pathways, and whether treating them changes outcomes beyond LDL reduction, remains an active area of study."
    },
    {
      "heading": "Diagnosis and Laboratory Evaluation",
      "text": "Standard lipid profile and sampling conditions\n\nThe 2026 ACC/AHA guideline, which retires and replaces the 2018 document, treats a standard lipid profile as the baseline test for both adults and children. Its purpose is to record starting lipid levels, estimate atherosclerotic risk, and decide whether lipid-lowering therapy should begin, and a nonfasting or fasting sample is acceptable. The profile reports total cholesterol, HDL cholesterol, and triglycerides, while LDL cholesterol is usually calculated rather than measured.\n\nLDL cholesterol: calculated or measured\n\nBecause ultracentrifugation was slow and costly, the equation was introduced into clinical practice in 1972 as a substitute for direct measurement. It estimates LDL-C by subtracting HDL-C and a triglyceride term from total cholesterol:\n\n\\[\\text{LDL-C} \\approx \\text{TC} - \\text{HDL-C} - \\frac{\\text{TG}}{5} \\quad (\\text{mg/dL})\\]\n\nThe estimate loses accuracy as triglycerides rise. In one large comparison with direct measurement, the Friedewald equation underestimated LDL-C by 9.0 mg/dL at triglyceride levels of 150–199 mg/dL, and the gap grew to 18.4 mg/dL at 200–399 mg/dL. Consequently, when triglycerides reach 150 mg/dL or more, the calculation often places patients below 70 mg/dL even when their measured LDL-C is at or above that cutoff. The formula cannot be applied when triglyceride levels exceed 400 mg/dL. Alternatives include the Martin–Hopkins equation, which in one Indian cohort demonstrated the best concordance with directly measured LDL-C, and the Sampson (NIH) equation, which extends to 800 mg/dL. European guidance still recommends the Friedewald-calculated LDL-C when triglycerides are below 400 mg/dL.\n\nNon-HDL cholesterol and apolipoprotein B\n\nNon-HDL cholesterol, calculated as total cholesterol minus HDL-C, captures the cholesterol carried by all atherogenic lipoproteins. It is easily calculated at no additional cost from a standard lipid profile, correlates well with apoB, and shows less discordance with apoB than LDL-C does. It is particularly useful when triglyceride levels are ≥150 mg/dL. The 2026 guideline recommends reporting it for risk assessment and treatment decisions.\n\nApolipoprotein B is a direct count of atherogenic particles, since each VLDL, IDL, and LDL particle carries one apoB molecule. Unlike the calculated lipids, apoB is measured directly, does not require fasting, and remains accurate when triglycerides are high or LDL-C is very low because of treatment. The guideline considers apoB reasonable to guide decisions about further therapeutic intensification once LDL-C and/or non–HDL-C goals are achieved in treated adults with ASCVD, diabetes, or elevated triglycerides, and may be reasonable to enhance ASCVD risk assessment in untreated adults. By contrast, advanced lipoprotein subclass testing is not recommended to estimate ASCVD risk and guide initiation of LLT as a routine measure, partly because lack of standardization across assays limits its use.\n\nLipoprotein(a)\n\nThe 2026 guideline states that lipoprotein(a) [Lp(a)] should be measured at least once to identify those individuals at higher risk of ASCVD. The recommendation is a Class 1 recommendation, the strongest, and it marks a change from the 2018 guideline, which mentioned Lp(a) only as a \"risk enhancer\" without a specific testing recommendation. The guideline counts levels ≥125 nmol/L (50 mg/dL) as a risk-enhancing finding, associated with about a 1.4-fold increase in ASCVD risk, and levels ≥250 nmol/L (100 mg/dL) with a risk at least twofold higher. The presence of elevated Lp(a) should be an indication for more intensified LDL-C lowering and management of other risk factors. Because the level is largely genetically determined and remains stable throughout your life, a single measurement is generally considered sufficient.\n\nSuspicion of genetic hyperlipidemia\n\nClinical features that raise suspicion for familial hypercholesterolemia include LDL-C at very high levels (for example ≥190 mg/dL), tendon xanthomas, and coronary disease at an early age. Family history is central: premature ASCVD in a first-degree relative (men under 55, women under 65 by common convention) and a relative with severe hypercholesterolemia both increase suspicion. Clinical scoring systems such as the Dutch Lipid Clinic Network criteria are used to estimate the likelihood of FH. For children, the guideline recommends screening with a lipid profile to identify familial hypercholesterolemia (FH) and other significant lipid disorders between ages 9 and 11, and cascade screening with a single lipid profile starting at ≥2 years of age is considered for relatives of affected individuals. Genetic testing for variants in LDLR, APOB, or PCSK9 is considered when the clinical picture points to a monogenic cause, since it can confirm the diagnosis and guide testing of relatives; a negative result does not exclude the diagnosis when clinical suspicion is strong. Severe hypertriglyceridemia with pancreatitis, or lipid patterns suggesting a rare recessive disorder, similarly prompt specialist evaluation.\n\nWork-up for secondary causes\n\nBefore attributing a lipid abnormality to a primary disorder, clinicians typically check for treatable acquired causes. Fasting glucose or HbA1c screens for diabetes and insulin resistance; TSH (with free T4 if abnormal) excludes hypothyroidism; creatinine with estimated GFR and a urine albumin or protein measurement identify chronic kidney disease and nephrotic syndrome; and liver enzymes and bilirubin help detect cholestatic liver disease. A review of medications, alcohol intake, and pregnancy status completes the evaluation."
    },
    {
      "heading": "Cardiovascular Risk Assessment",
      "text": "Multivariable risk equations\n\nDecisions about lipid-lowering therapy in adults without clinical disease rest on an estimate of absolute risk, not on a lipid value alone. The 2026 ACC/AHA multisociety guideline, which replaced the 2018 cholesterol guideline, uses the PREVENT equations for this estimate. The guideline recommends the PREVENT equations as the preferred tool for estimating cardiovascular risk in adults aged 30–79 years, replacing the older Pooled Cohort Equations. The older Pooled Cohort Equations are no longer supported by ACC clinical policy or guidelines.\n\nThe PREVENT models were developed by the American Heart Association and are intended for adults without known cardiovascular disease. They can be used for adults ages 30–79 without known cardiovascular disease. Their inputs include age, high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), systolic blood pressure (SBP), estimated glomerular filtration rate (eGFR), diabetes status, current smoking status, and treatment with anti-hypertensive or statin medication. The models are race-free, and they estimate separate outcomes: total cardiovascular disease (CVD), including atherosclerotic CVD (ASCVD) and heart failure (HF). Lipid-lowering decisions use the ASCVD outcome, which covers myocardial infarction and ischemic stroke.\n\nTen-year and thirty-year horizons\n\nThe ten-year estimate is the main decision variable. The thirty-year estimate is secondary and matters mostly for younger adults. The 30-year risk estimates are only available for individuals 30 to 59 years of age. The longer horizon addresses a specific problem: a younger adult with one or more risk factors may have a low 10-year risk while the lifetime burden is substantial. In the AHA's development paper, a 50-year-old woman with a listed profile had an estimated 10-year total CVD risk of 5.4%, but a 30-year estimate of 31%, and the 30-year figure rose further when smoking was added.\n\nRisk categories and intensity of intervention\n\nThe 2026 guideline divides 10-year PREVENT-ASCVD risk into four groups: low (<3%), borderline (3% to <5%), intermediate (5% to <10%), and high (≥10%). The PREVENT-ASCVD equations should be used to estimate 10-year ASCVD risk, with categorization as having low (<3%), borderline (3% to <5%), intermediate (5% to <10%), or high (≥10%). These cutoffs are not exact equivalents of the older Pooled Cohort Equations thresholds, which were set at different levels; the guideline's table gives approximate equivalent ranges for the two systems.\n\nIntensity rises with category. Low-risk adults are generally managed with lifestyle measures. For borderline adults, LDL-lowering therapy can be considered after a clinician–patient discussion, and for intermediate-risk adults it should be considered. For high-risk adults the guideline sets a stricter goal: an LDL-C below 70 mg/dL for individuals at high risk as calculated by the PREVENT-ASCVD risk equations, while those at low, borderline, or intermediate risk are directed to an LDL-C below 100 mg/dL. Target values are discussed further in the treatment section.\n\nRisk-enhancing factors\n\nRisk-enhancing factors can move an adult to a more intensive decision when the estimate is near a threshold. For borderline adults, the guideline asks clinicians to consider any risk enhancers, including family history of early-onset ASCVD in parents or siblings (<55 years for men or <65 years for women) and higher risk ancestry, including South Asian and Filipino. Among young adults, early consideration of pharmacotherapy applies to those with LDL cholesterol (LDL-C) ≥160 mg/dL or a strong family history of premature atherosclerotic cardiovascular disease (ASCVD). Other recognized enhancers include chronic kidney disease and elevated triglycerides, which the guideline weighs together with the calculated estimate rather than as fixed thresholds.\n\nCoronary artery calcium scoring\n\nCoronary artery calcium (CAC) scoring measures calcified plaque in the coronary arteries and is used to refine risk when the decision is unclear. In adults at intermediate risk and select adults at borderline risk with no prior ASCVD, if the decision about lipid-lowering therapy remains uncertain, a CAC score should be used for further risk stratification. The result then guides the next step. A score of zero is associated with deferring therapy: in adults at intermediate risk or select adults at borderline risk, a CAC score of 0 Agatston units (AU) allows deferring therapy and reassessing with repeat CAC testing in 3 to 7 years. A higher score favors treatment: if the CAC score is above 0 AU, it is recommended to initiate lipid-lowering therapy, particularly if the score is ≥100 AU or at or above the 75th standardized percentile.\n\nCAC scoring is intended to reclassify risk rather than define it. These recommendations come from an abundance of data supporting the use of a CAC score to reclassify risk, not define it. Reclassification gains also depend on an earlier risk estimate: the reclassification gain documented is, by definition, conditional on having estimated baseline risk first. Earlier guidance did not recommend CAC scoring for adults with established ASCVD, where it adds no decision value in that group."
    },
    {
      "heading": "Treatment Goals and Targets",
      "text": "From percentage reductions back to numeric goals\n\nThe 2018 US guideline centered on relative LDL-C reduction rather than absolute cutoffs, and the 2026 guideline reverses that emphasis, returning to specific numeric targets. The 2026 ACC/AHA multisociety guideline replaced the 2018 cholesterol guideline and explicitly restored LDL-C and non-HDL-C goals as parallel treatment targets. Non-HDL-C goals are generally set 30 mg/dL above the corresponding LDL-C goal across the principal risk categories. Commentators describe this as moving the US framework closer to the target-based approach long used in Europe. The return to explicit LDL-C and non-HDL-C goals also brings the US recommendations closer to the target-based European framework.\n\nThe percentage approach has not been discarded. Clinical summaries describe the guideline as aiming for percentage LDL-C reduction based on individual risk level in addition to absolute targets, so the two measures are used together rather than one replacing the other.\n\nPrimary prevention by risk tier\n\nTargets for people without established atherosclerotic disease depend on estimated 10-year risk, calculated with the PREVENT-ASCVD equations. In adults at borderline (3% to <5%) or intermediate (5% to <10%) 10-year risk who are being initiated on statin therapy, it is reasonable to treat to an LDL-C goal of <100 mg/dL and non–HDL-C <130 mg/dL. Adults in the high-risk group (≥10%) have an event risk that is similar to patients with established ASCVD, warranting intensification of LLT, with the goal of attaining an LDL-C goal of <70 mg/dL and non–HDL-C <100 mg/dL.\n\nCoronary artery calcium (CAC) scores can move a person into a stricter tier. In adults with a CAC score of ≥1000 AU, treatment with LDL-C–lowering therapies with consideration of statin therapy as first line is recommended to achieve a ≥50% reduction in LDL-C and a goal of LDL-C <55 mg/dL and non–HDL-C <85 mg/dL. For scores of 300 to 999 AU, the recommended goal is LDL-C <70 mg/dL and non–HDL-C <100 mg/dL. Having any amount of CAC supports an LDL-C goal of <100 mg/dL, with lower LDL-C target levels with higher amounts of calcium. ApoB may also serve as a secondary marker. Once LDL-C and non-HDL-C goals have been met, testing ApoB levels can be useful to assess risk and guide treatment, particularly in people with high triglycerides, diabetes, or LDL-C below 70 mg/dL. For ApoB itself, an ApoB <55 mg/dL may be reasonable in severe hypercholesterolaemia with established ASCVD.\n\nSecondary prevention and very low LDL-C\n\nFor adults with established atherosclerotic disease, the guideline separates patients at very high risk from the rest. Very high risk is defined by ≥2 major ASCVD events, or 1 major event plus ≥2 high-risk conditions. For this group, LDL-C below 55 mg/dL and non-HDL-C below 85 mg/dL are the goals. Patients with clinical ASCVD who are not classified as very high risk have a goal of LDL-C <70 mg/dL. The guideline notes that the majority of those with a history of ASCVD events will likely qualify for an LDL-C goal of <55 mg/dL.\n\nThe evidence for these lower goals rests on several sources. The Cholesterol Treatment Trialists' meta-analysis reported that there was a 22% reduction in major vascular events per 1-mmol/L (38.7-mg/dL) lowering of LDL-C, and the 2010 analysis of 26 trials found that there was no evidence of any threshold within the cholesterol range studied, which suggested that a further reduction of 2 to 3 mmol/L would reduce risk by roughly 40% to 50%. A 2026 meta-analysis of primary prevention outcome trials estimated a 30% relative risk reduction in 4-point MACE per 1 mmol/L reduction in LDL-C. For the newest threshold, the significant cardiovascular benefits with more intensive lowering of LDL-C to <55 mg/dL in patients without previous MI or stroke in VESALIUS-CV have been cited by guideline authors as a reason to revisit how risk categories are defined. Safety data for very low levels have also been reviewed. Safety data extend to a median LDL-C of 30 mg/dL, with no de-escalation signal at very low levels. Some researchers still debate how much additional benefit comes from lowering LDL-C that is already very low; the magnitude of clinical benefit of further LDL-C lowering in patients already with very low LDL-C levels remains debated.\n\nPercentage-reduction targets\n\nPercentage goals specify how much a therapy should lower LDL-C from its untreated level, and they are paired with absolute goals. For high-risk and very-high-risk patients, the guideline recommends first-line high-intensity statin therapy aiming for a ≥50% reduction. For incidental CAC findings in lower-risk adults, moderate-intensity statin therapy is reasonable to achieve a ≥30% to 49% reduction in LDL-C and a goal of LDL-C <100 mg/dL and non–HDL-C goal <130 mg/dL. In the 100 to 299 AU CAC range, a ≥50% reduction is not mandated for every patient in this group — set intensity individually.\n\nThe rationale for percentage targets comes from the relationship between LDL-C lowering and event reduction. Meta-analyses of LDL-C–lowering therapy found that event reduction correlates with the extent of LDL-C reduction. Percentage targets also account for different starting levels. A reduction that is proportionate for one patient may not be sufficient for another, while an absolute goal shows whether the endpoint has been reached. Analyses note the practical consequence of this: for some patients, a target of 55 or even 40 mg/dL requires lipid-lowering therapy to reduce LDL-C by 70%–80%. Percentage and absolute goals therefore act as complementary checks on the same treatment."
    },
    {
      "heading": "Pharmacological Therapy",
      "text": "Drug therapy is layered on top of lifestyle measures. The choice of agent depends on which lipoprotein abnormality dominates, how far LDL cholesterol must fall, and whether atherosclerotic disease is already present.\n\nStatins\n\nStatins are the first-line drugs for raised LDL cholesterol. They competitively block HMG-CoA reductase, the enzyme that limits hepatic cholesterol synthesis. Lower intracellular cholesterol then increases transcription of the LDL receptor gene, so more LDL particles are removed from plasma. This receptor-mediated effect is the main reason statins lower LDL-C.\n\nClinical potency is grouped by expected LDL-C reduction. High-intensity statin therapy is expected to lower LDL-C levels by ≥50%, moderate-intensity statin therapy by ≥30% to 49%, and low-intensity statin therapy by <30%. Preferred high-intensity regimens are atorvastatin 40–80 mg and rosuvastatin 20–40 mg, while moderate-intensity options include atorvastatin 10–20 mg and rosuvastatin 5–10 mg.\n\nIntensity is matched to risk. Patients with clinical ASCVD who are at very high risk should also receive high-intensity statin therapy first line; addition of ezetimibe and/or a PCSK9 monoclonal antibody is recommended if treatment intensification is needed to achieve lipid goals.\n\nAdd-on LDL-lowering agents\n\nWhere statins alone fall short, several add-on classes are used. Ezetimibe blocks intestinal cholesterol absorption. Its LDL-C effect is roughly 18–20%, and its cardiovascular benefit was established in the IMPROVE-IT trial. Ezetimibe is a generic, well-tolerated first-line add-on.\n\nPCSK9 monoclonal antibodies bind circulating PCSK9 so that it cannot degrade LDL receptors, and they are given by injection. Injectable PCSK9 antibodies lower LDL-C by about 60%, against 15–20% for ezetimibe, which is why early combination is often needed in peripheral arterial or polyvascular disease. Given that PCSK9 inhibitors can achieve approximately 60% LDL-C reduction compared with 15-20% for ezetimibe, early combination therapy is often necessary in patients with PAD or polyvascular ASCVD.\n\nBempedoic acid is an oral agent that acts upstream of HMG-CoA reductase in the liver, a feature often cited for its use when statin-related muscle symptoms occur. Try an alternative statin or reduce the dose; bempedoic acid (COR 1), ezetimibe and PCSK9 monoclonal antibodies are options. Inclisiran, an siRNA-based agent, is second-line where a monoclonal antibody is not tolerated or accessible. Whether its LDL-C lowering translates into better outcomes and fewer cardiac events is still being studied in clinical trials.\n\nThe 2026 framework has also changed sequencing. Unlike earlier recommendations that mandated a stepwise sequence of statin followed by ezetimibe and then PCSK9 inhibitors, the current framework allows clinicians to select among ezetimibe, PCSK9 inhibitors, and bempedoic acid, based on the magnitude of LDL-C reduction required and patient-specific factors. For severe hypercholesterolemia, treatment with maximally tolerated statin therapy is recommended for all patients with severe hypercholesterolemia (regardless of FH status). If lipid goals are not achieved on statin therapy alone, the addition of ezetimibe, a PCSK9 monoclonal antibody, and/or bempedoic acid is recommended.\n\nAgents used mainly for triglycerides\n\nFibrates are PPARα agonists that act mainly on triglyceride-rich lipoproteins. Fibrates reduce TG levels by 25-50% and increase HDL-C by 5-20%. The effect on LDL-C is variable. Outcome data are more favorable in selected subgroups. A pooled analysis of patients with triglycerides above 200 mg/dL found a roughly 25% reduction in vascular events, and about 29% in those whose HDL-C was also below 40 mg/dL. In a meta-analysis of 7389 patients with high TGs (>200 mg/dL [2.3 mmol/L]), fibrate therapy decreased vascular events by 25%, and in the 5068 patients with both high TGs and low HDL-C (<40 mg/dL [1 mmol/L]), a 29% decrease in vascular events was observed. By contrast, in the ACCORD trial, the combination of fenofibrate and simvastatin did not reduce the rate of fatal CV events, non-fatal MI, or non-fatal stroke compared with simvastatin alone.\n\nNiacin lowers triglycerides and also reduces lipoprotein(a); niacin decreases total cholesterol, TGs (20-50% decrease), LDL-C, and Lp(a). Its outcome record is weak: in patients with established CV disease, the combination of niacin and LDL-lowering therapy did not reduce CV events; though, niacin showed a trend towards benefit in the subset of patients within the study group.\n\nOmega-3 fatty acids present the most mixed picture. While data support the causal relationship between triglycerides and ASCVD risk, triglyceride-lowering therapies such as omega-3 fatty acids have shown mixed results in CV outcomes trials. A prescription EPA-only product is the clearest positive result: in one large trial, it lowered a composite of cardiovascular events by 25% among statin-treated patients with elevated triglycerides. Non-prescription fish oil products are not interchangeable with these agents.\n\nIndications in diabetes, chronic kidney disease, HIV, and young adults\n\nIn adults aged 40 to 75 with diabetes and no established ASCVD, the guideline prescribes moderate-intensity statin with the aim of a 30–49% reduction in LDL-C, LDL-C <100 mg/dL, and non-HDL-C <130 mg/dL. When multiple ASCVD risk factors are present, high-intensity statin is considered, aiming for ≥50% LDL-C reduction and LDL-C <70 mg/dL. The 2026 update also uses an age-stratified approach (20–39, 40–75, >75) for diabetes.\n\nFor chronic kidney disease, in adults 40 to 75 years of age with CKD stage 3 or higher and an LDL-C of 70 to 189 mg/dL (1.8–4.9 mmol/L), moderate-intensity statin therapy or moderate-intensity statin combined with ezetimibe is recommended to reduce ASCVD risk. Note that this recommendation is bounded by an LDL-C window, unlike the diabetes profile. HIV appears as a new population in the 2026 update, with a statin recommended.\n\nFor young adults, the approach is graded by risk. In adults aged 30 to 59 years, at low (<3%) 10-year estimated risk for ASCVD who have an LDL-C <160 mg/dL (4.1 mmol/L) and a 30-year risk estimate of <10%, counseling on health behaviors is recommended to reduce LDL-C and risk for ASCVD. In adults aged 30 to 59 years, at low (<3%) 10-year estimated risk for ASCVD but with an LDL-C of 160 to 189 mg/dL (4.1-4.9 mmol/L) or a 30-year ASCVD risk ≥10% (for those aged 30-59 years), a moderate-intensity statin is reasonable to reduce cumulative exposure to atherogenic lipoproteins."
    },
    {
      "heading": "Lifestyle and Nonpharmacological Management",
      "text": "Lifestyle change is the first layer of dyslipidemia care in current guidance, although its effect differs by lipid. The 2026 ACC/AHA guideline retires and replaces the 2018 AHA/ACC cholesterol guideline, and it treats habits as a lifelong project. For children and healthy adults, it asks clinicians to promote healthy eating, regular activity, a healthy body weight, good sleep, stress management and avoidance of tobacco, to reduce the risk for dyslipidemia and ASCVD. Health behavior counseling should start in youth, and the guideline links early counseling with later decisions about drug therapy.\n\nDiet is the most heavily emphasized component. The guideline's preferred pattern centers on vegetables, fruit, nuts, whole grains, legumes and healthy fats, with reduced saturated fat and avoidance of trans fat, and clinicians may suggest the DASH or a vegetarian diet (fruit, vegetables, nuts, whole grains, legumes, and healthy fats, with reduced saturated fat and trans-fat avoidance). Dietary fiber, found mainly in whole grains, legumes and produce, is part of this pattern. A secondary summary of the guideline reports that Mediterranean and DASH-style eating can lower LDL-C by about 10–15% and triglycerides by about 10–20% Mediterranean and DASH diets reduce LDL-C by 10-15% and triglycerides (TG) by 10-20%. The direct LDL effect of diet is usually more modest than its broader benefits, since healthy eating patterns provide multiple cardiovascular benefits, including weight reduction, decreased inflammation, and improved control of blood pressure and glucose, while the LDL-C reduction itself tends to be smaller. Dietary supplements are not recommended to lower LDL-C or triglycerides, because their efficacy data are limited Do not recommend dietary supplements to reduce LDL-C or TG, due to limited efficacy data.\n\nDiet has its strongest lipid effect in hypertriglyceridemia, where it is the first-line treatment. Lifestyle management represents the first line of therapy for the treatment of hypertriglyceridemia, with a more than 70% reduction in TG noted in highly responsive individuals. The restrictions scale with the triglyceride level. At fasting values of 150–499 mg/dL, the advice centers on cutting added sugar, refined carbohydrates and saturated fat while keeping alcohol minimal. At 500–999 mg/dL, alcohol is eliminated entirely and total fat is individually limited, because the goal shifts toward reducing pancreatitis risk Fasting TG 500–999 mg/dL (5.7–11.3 mmol/L) | Diet: low added sugar, refined carbohydrates, and saturated fat Complete elimination of alcohol Individualized total fat limit. In familial chylomicronemia, a much stricter fat restriction is used to prevent pancreatitis To prevent pancreatitis in patients with FCS, a very low-fat diet (<15% of calories from fat, <20 g/day) is used.\n\nPhysical activity acts on triglycerides and HDL more than on LDL. The guideline's aerobic benchmark is 150 minutes per week of moderate activity or 75 minutes of vigorous activity, supplemented by resistance training on two days a week adequate physical activity (at least 150 minutes per week of accumulated moderate-intensity or 75 minutes per week of vigorous-intensity aerobic physical activity, plus 2 days per week of upper and lower body resistance exercise). One summary attributes to such exercise a triglyceride reduction of 10–20% and an HDL increase of 5–10% Regular aerobic exercise (150 minutes of moderate-intensity or 75 minutes of high-intensity per week) reduces TG levels by 10-20% and increases \"good cholesterol\" (HDL-C) by 5-10%. Evidence for lipid benefit from exercise alone is mixed, and a 12-week randomized trial in people with obesity found exercise raised HDL cholesterol by 16%, while calorie restriction and alternate-day fasting lowered LDL cholesterol by 8–10%. Such comparisons show that diet and exercise act through partly different routes.\n\nWeight loss is closely tied to lipid change, but its effect on HDL is not linear. In a meta-analysis of 70 weight-loss studies, HDL-C fell during weight loss and rose once body weight stabilized In a meta-analysis of 70 weight-loss studies, HDL-C decreased during weight loss and increased when weight stabilized. The Look AHEAD trial, in adults with type 2 diabetes, showed a more durable pattern. Over four years, the intensive lifestyle group had clearly greater weight loss and triglyceride reduction than the control group, and their HDL cholesterol was 1.70 mg/dL higher on average HDL Cholesterol (mg/dl) 1.97 (1.73, 2.22) 3.67 (3.43, 3.91) +1.70 <0.0001. Combining a healthy diet with weight loss and physical activity has been reported to raise HDL-C by 10–13% Combining a healthy diet with weight loss and physical activity can increase HDL-C 10% to 13%.\n\nTobacco cessation, sleep, stress and alcohol form the remaining modifiable set. Regular brisk physical activity, maintaining a normal weight, and tobacco cessation and abstinence are also associated with more favorable lipids and cardiovascular outcomes. Healthy sleep and stress management appear in the guideline's core list, while alcohol is limited to minimal intake at moderate triglyceride levels and removed entirely at higher ones. Lifestyle measures do not substitute for drug therapy where it is indicated. Lifestyle changes minimally affect Lp(a) levels, so repeat testing is generally not needed. Combined programs can produce larger effects than either approach alone: in one review, exercise plus a diet low in saturated fat reduced LDL cholesterol by 7–15% and triglycerides by 4–18%, while raising HDL cholesterol by 5–14% Exercise plus a low–saturated fat diet reduced LDL cholesterol levels by 7 to 15 percent and triglyceride levels by 4 to 18 percent, while increasing HDL cholesterol levels by 5 to 14 percent. The 2026 guideline accordingly presents habit change and cholesterol-lowering medication as complementary, not alternative, parts of the same care pathway."
    },
    {
      "heading": "Special Populations",
      "text": "Children and adolescents\n\nCurrent US guidance treats childhood as the period for detection and early intervention. In children 9 to 11 years of age not previously tested, it is recommended to screen with a lipid profile to identify familial hypercholesterolemia (FH) and other significant lipid disorders. The reason is that family history alone misses many affected children: up to half of those with a high LDL-C do not report a family history of hypercholesterolemia or premature ASCVD. Lifestyle counseling is the first step for children with lipid abnormalities, but drug therapy becomes appropriate in defined circumstances. In children and adolescents aged 8 years or older with an LDL-C persistently at or above 160 mg/dL and a presentation consistent with FH, who do not respond sufficiently after 3 to 6 months of lifestyle management, starting a statin and other lipid-lowering therapy as needed is recommended. In trials, statins lower LDL-C with minimal adverse effects and stabilize or reduce subclinical atherosclerosis. Pediatric trials have also tested ezetimibe, PCSK9 monoclonal antibodies, and bile acid sequestrants, while inclisiran is not FDA-approved for use in children under 18. Homozygous FH is a separate situation: affected individuals can present with coronary obstruction in childhood and need aggressive lipid-lowering treatment from diagnosis, often in infancy.\n\nYoung adults\n\nThe 2026 guideline places emphasis on earlier treatment to limit lifelong exposure to atherogenic lipoproteins. Early consideration of pharmacotherapy is recommended in youth with FH and in young adults with LDL-C of 160 mg/dL or higher, or a strong family history of premature atherosclerotic cardiovascular disease. Diabetes duration and complications also shift the threshold for young adults. In adults aged 20 to 39 with long-standing diabetes, albuminuria, reduced eGFR, retinopathy, neuropathy, or an ankle-brachial index below 0.9, a moderate-intensity statin may be reasonable to reduce ASCVD risk. The guideline also extends primary-prevention risk estimation downward: the population target for ASCVD risk estimation was expanded from ages 40 to 75 years in the 2018 guideline to ages 30 to 79 years in the 2026 guideline.\n\nPregnancy and lactation\n\nLipid-lowering drugs are generally withdrawn around conception, and the reasoning rests largely on preclinical data. For persons of childbearing age with hypercholesterolemia who are not at high risk for ASCVD and plan to become pregnant, the guideline advises stopping statins 1 to 2 months before attempting to become pregnant or as soon as pregnancy is discovered. Statin avoidance rests on earlier animal and preclinical studies that raised concerns for teratogenicity in humans, although the doses used in animals were much higher than clinical doses and later studies have produced conflicting results. Exceptions exist for high-risk patients. In pregnant individuals with FH or a history of clinical ASCVD, it may be reasonable to continue statin therapy following an individualized benefit-risk discussion. Other options differ by agent. In pregnant or lactating individuals with hypercholesterolemia but without hypertriglyceridemia, bile acid sequestrants are reasonable to lower LDL-C, and in pregnant individuals with severe fasting hypertriglyceridemia (TG ≥500 mg/dL), fibrates after the first trimester or high-dose omega-3 ethyl esters are reasonable as an adjunct to lifestyle management. Ezetimibe, PCSK9 monoclonal antibodies, bempedoic acid, and inclisiran should generally be avoided because of insufficient pregnancy safety data, and statins should be avoided during lactation. For women with HoFH, lipoprotein apheresis is reasonable to lower LDL-C and reduce ASCVD risk during pregnancy or lactation. Because conception and breastfeeding can take considerable time, an individual may have to defer systemic lipid-lowering therapy, especially statins, for a period of 1 year, and possibly several years.\n\nRegulatory and professional positions are not uniform. The FDA removed its strongest warning against statin use in pregnancy, recommending individualized decision-making for women at very high cardiovascular risk. A 2024 European review, by contrast, still describes statins as contraindicated in pregnancy, while accepting an individual decision in severe hypercholesterolemia. For breastfeeding, UK reference guidance indicates that the amount of pravastatin and atorvastatin in breast milk is very low, which differs from the US position of avoidance.\n\nOlder adults\n\nFor older adults, the 2026 guideline asks that treatment decisions weigh more than age alone. The benefit-risk discussion should include patient priorities, functional status, multimorbidity, frailty, polypharmacy, and life expectancy, and should not be based solely on chronological age. A central consideration is time to benefit. A recent meta-analysis estimated that approximately 2.5 years of statin treatment are needed to prevent one major adverse cardiovascular event per 100 patients treated. Evidence for older people is limited, since the major randomized controlled trials that established the benefits of statins in preventing atherosclerotic cardiovascular disease generally did not enroll persons older than 75 years. The USPSTF has taken a cautious position, stating that the current evidence is insufficient to assess the balance of benefits and harms of initiating a statin for the primary prevention of CVD events and mortality in adults 76 years or older. The guideline is more specific for people with diabetes: in adults over 75 with diabetes and an estimated life expectancy of at least 2.5 years, it may be reasonable to initiate moderate-intensity statin therapy after a discussion of potential benefits and risks. Where life expectancy is short, the balance shifts. When life expectancy is under one year, discontinuing lipid-lowering therapy prescribed for primary prevention may be considered. One randomized trial in patients with estimated life expectancy under one year found that discontinuing statin therapy was safe and associated with improved quality of life. Two ongoing trials, STAREE and PREVENTABLE, are expected to clarify the role of statins in people over 70 and over 75."
    },
    {
      "heading": "Monitoring, Adherence, and Adverse Effects",
      "text": "Follow-up lipid testing\n\nThe 2026 ACC/AHA dyslipidemia guideline recommends a lipid profile 4 to 12 weeks after starting or changing lipid-lowering therapy, then every 6 to 12 months, to check both drug efficacy and adherence. Response is judged in two ways: the percentage fall in LDL-C from baseline and whether absolute LDL-C and non-HDL-C goals are reached. Later testing intervals are individualized according to ASCVD risk, the LDL reduction still needed, the drug used, the time to steady state, adherence, and how stable the values have been. A patient whose therapy is unchanged, whose response is stable, and who has no clinical change may be tested once a year. Nonfasting samples are sufficient in most cases, while fasting samples are needed when hypertriglyceridemia is known. Because statin response varies considerably and is linked to future events, an inadequate response prompts intensification of lifestyle measures or the statin regimen.\n\nStatin-associated muscle symptoms\n\nMuscle complaints are the most frequently cited reason for stopping statins. Blinded randomized evidence shows a much smaller effect than patients often expect. In placebo-controlled trials pooled by the Cholesterol Treatment Trialists' Collaboration, muscle pain or weakness was reported by 27.1% of statin-treated and 26.6% of placebo-treated participants, and the small excess was concentrated in the first year of treatment. The ASCOT-LLA trial found similar muscle-symptom rates on statin and placebo during blinding, but a higher rate once patients knew they were taking a statin, which points to a nocebo contribution. The SAMSON N-of-1 trial, in which participants alternated between statin and placebo periods, reported symptom burdens that were similar on both, and the trial's investigators attributed nearly all of the symptoms to nocebo. No objective diagnostic test for statin-associated muscle symptoms exists. Evaluation therefore relies on symptom characterization, exclusion of alternative causes such as hypothyroidism, interacting drugs, strenuous exertion, and renal impairment, and, when symptoms are severe, measurement of creatine kinase to exclude rhabdomyolysis, which is rare. Routine periodic liver tests are no longer required for all patients; liver enzyme measurements are generally obtained when clinically indicated, since statins can raise aminotransferases, usually modestly.\n\nNew-onset diabetes\n\nStatins are associated with a small increase in the risk of new-onset diabetes. Early meta-analyses of randomized trials estimated a relative increase of roughly 9% to 13%, and a pooled analysis of five trials found that intensive-dose therapy carried more risk than moderate-dose therapy. One trial-based meta-analysis reported a larger risk when LDL-C was reduced by 30% or more, and an observational meta-analysis reported a higher pooled relative risk, although it showed very high heterogeneity and is vulnerable to confounding. The cardiovascular benefit of statins is considered to outweigh this excess risk for most patients, and a number-needed-to-harm versus number-needed-to-treat comparison from one analysis supports that view. Clinical practice responds by monitoring glucose and insulin-resistance-related risk markers, particularly in people with prediabetes, obesity, elevated triglycerides, or hypertension, who have the highest baseline risk.\n\nCauses of nonadherence and strategies to address them\n\nDiscontinuation is a major problem in secondary prevention. Estimates suggest that between half and three-quarters of people prescribed a statin stop taking it within two years, and many others decline treatment because of concerns about side effects. Drivers include perceived or real adverse effects, cost, pill burden, multiple concurrent prescriptions, forgetfulness, and the patient's beliefs about medicines. Strategies include simplifying the regimen, for example with once-daily dosing or fixed-dose combinations; shared decision-making; written information explaining which symptoms are common and benign; symptom diaries; and reminders for refills and laboratory testing. Patient education about the nocebo effect is a central component, since informing patients that their symptoms may not be caused by the drug has been associated with successful resumption of therapy in recent studies.\n\nManagement of statin intolerance\n\nThe term \"statin intolerance\" is used less often than it once was, because many clinicians now describe the problem as statin-associated muscle symptoms, a designation that separates the reported symptom from its cause. The management sequence typically begins with confirming the symptom pattern and treating reversible contributors. If symptoms persist, a rechallenge can be guided by a structured approach, such as a blinded or self-controlled trial of statin and placebo. Options then include reducing the dose, switching to a different statin, or using intermittent dosing, with each step judged by symptom tolerability and the LDL-C response. Nonstatin agents are added when the statin cannot be tolerated or when additional lowering is required. Ezetimibe, which blocks intestinal cholesterol absorption, is the usual first add-on, either alone or combined with a low-dose statin. PCSK9 monoclonal antibodies provide substantially greater LDL reduction and are reserved for patients who remain above their targets or who cannot take statins. Bempedoic acid, which is activated in the liver, is an alternative for patients with statin-related muscle complaints. The order in which these agents are introduced depends on baseline risk, the degree of LDL reduction required, cost, and the patient's preferences."
    },
    {
      "heading": "Epidemiology and Global Burden",
      "text": "Prevalence across populations\n\nA 2025 systematic review and meta-analysis pooled 206 studies, primarily cross-sectional, published between 2000 and 2025. It estimated that the global prevalence was 28.8% for hypertriglyceridemia, 24.1% for hypercholesterolemia, 38.4% for low HDL-C, and 18.93% for high LDL-C. The same analysis found that men presented a higher prevalence of hypertriglyceridemia (33.8% vs. 24.5% in women), while women had higher rates of low HDL cholesterol. These figures are lower than older benchmarks. The WHO, whose most recent global estimate dates from 2008, put adult hypercholesterolemia at 39 %, and the World Heart Federation applies a total cholesterol threshold of (≥5.0 mmol/L) in its roadmap. The gap probably reflects differences in thresholds, data sources and study design rather than a clear trend.\n\nRegional variation is large. The earlier WHO regional estimates put adult hypercholesterolemia at 53.7% in Europe and 47.7% in America, while South East Asia (30.3%) and Africa (23.1%) had much lower prevalence. Within Asia, one review reported marked prevalence differences between different Asia Pacific countries, ranging from 9% in Indonesia to 46.9% in the Philippines. Data from South and Southeast Asia remain sparse, with FH prevalence estimates missing for majority of the countries of the region.\n\nFamilial hypercholesterolemia: prevalence and underdiagnosis\n\nFamilial hypercholesterolemia (FH) is among the most common single-gene disorders. A pooled analysis of general-population studies found an overall pooled prevalence of FH was 1:311, with similar rates in children and adults and across WHO regions. Among people with atherosclerotic cardiovascular disease, the frequency was far higher, with a pooled figure of 1:17. Homozygous FH is much rarer, with a worldwide prevalence estimated between 1/160,000 and 1/320,000.\n\nDiagnosis lags well behind these estimates. In the United Kingdom, a primary-care database study estimated the estimated familial hypercholesterolaemia prevalence for the UK was 16.4 per 10 000, which the authors judged to be less than expected from other studies, which may indicate that familial hypercholesterolaemia is under-recognised in UK primary care. In Ireland, the Irish Heart Foundation estimates at least 10,000 people in Ireland have FH, and most cases are likely to be undiagnosed. Treatment is also incomplete among those who are identified: a collaborative study found that about 40% of individuals with a familial hypercholesterolaemia diagnosis may not be receiving any lipid-lowering therapy.\n\nTreatment rates, control and disparities\n\nEven among high-risk patients, treatment and control remain inadequate. In the EURIKA study of primary prevention patients in 12 European countries, among high-risk individuals, 65.3% were receiving lipid-lowering therapy, and 61.3% of treated patients had uncontrolled low-density lipoprotein cholesterol (LDL-C) levels. A more recent multinational study, SANTORINI, found that 21.8% of patients had no documented LLTs, 54.2% were receiving monotherapy and 24.0% combination LLT. Goal attainment was low in both groups, with 20.9% (1023/4902) and 32.3% (700/2169) were at goal, respectively. After acute myocardial infarction, a global database analysis found that only 7–12% of patients were reported to have LDL-C values < 55 mg/dL.\n\nTrends over time are mixed. In the United States, utilization of therapy increased from 30.3% (95% CI: 26.0%-35.0%) prepandemic to 35.8% (95% CI: 30.7%-41.2%) postpandemic, and among non-Hispanic Black adults the rise was steeper, from 23.0% to 31.9%. Among adults with established atherosclerotic disease, the increase was not statistically significant. A nationwide study of FH covering 1996 to 2021 noted after 2009 there was a stagnation in the hitherto increasing use of statins. Disparities also appear by sex: in a Chinese cohort, women had a significantly lower LDL-C goal attainment rate than that of men (46.0% vs 53.8%, P = 0.002), and approximately 50% of the gender disparity remained unexplained by these factors. Socioeconomic and access-related inequalities are discussed in more detail in social determinants of health.\n\nContribution to global cardiovascular mortality\n\nCardiovascular disease is the leading cause of death worldwide, and dyslipidemias are among its major modifiable risk factors. The World Heart Federation's roadmap reports that in 2019, high non-HDL cholesterol was linked to an estimated 4.4 million deaths. Because LDL lowering reduces events, the benefit is considerable at the population level: a large meta-analysis found that each 1 mmol/L reduction in LDL cholesterol was associated with a 19% relative risk (RR) reduction for major vascular events. Given the undiagnosed burden and treatment gaps, researchers have argued for public health policies, including screening programs, to identify FH early and to prevent its global burden, a topic addressed further in public health policy."
    },
    {
      "heading": "Public Health Policy and Screening",
      "text": "Population screening strategies\n\nCountries differ mainly in whether they test whole age groups or only people with identifiable risk. In the United States, the National Heart, Lung, and Blood Institute recommended in 2011 that all children be screened between ages 9 and 11 and again between 17 and 21, a recommendation endorsed by the American Academy of Pediatrics. Uptake has been low: recent data suggest only 2% to 22% of US children are screened in the 9-to-11 window. The US Preventive Services Task Force has taken a more cautious position, issuing an \"I\" statement in 2016 (renewed in 2023) that evidence is insufficient to recommend for or against universal pediatric lipid screening. This disagreement has been a major reason for inconsistent practice.\n\nOther countries have chosen different entry points. Slovenia runs a national program of universal screening for familial hypercholesterolemia that begins at about age five, and its preschool program is being evaluated in a cohort study. Earlier UK screening was typically initiated around age ten. Outside the United States, universal lipid screening has often been judged too expensive, so cases are usually found later through clinical services, where genetic testing helps stratify risk.\n\nCascade screening of relatives\n\nFamilial hypercholesterolemia is autosomal dominant, so a diagnosed index patient usually has relatives who share the variant. Cascade screening systematically tests these relatives. Economic analyses are generally favorable: a 2023 systematic review found cascade screening cost-effective in 78% of reported incremental cost-effectiveness ratios, and it yielded the largest health benefit per person tested among the strategies compared. An early UK model estimated a ratio of about £5,806 per case-related outcome, with more than 80% of lifetime costs incurred in the first year after diagnosis. A synthesized estimate placed cascade screening at roughly US$49,630 per quality-adjusted life year. Benefit depends heavily on how far the search extends. A US simulation found testing of first-degree relatives cost-effective, but testing became unfavorable when started at age 40 or later, and testing of more distant relatives generally did not pay off. Real-world uptake also matters: modeling studies that assumed nearly all relatives would accept testing overstated cost-effectiveness, and low acceptance rates have been reported in several programs.\n\nFood policy and trans fats\n\nPopulation measures aimed at diet have focused on industrially produced trans fat. Denmark was the first country to act, passing a law in 2003 that limited trans fat to 2% of fats and oils in all foods, and this law became a template for others. In 2018 the World Health Organization launched the REPLACE initiative, a six-module action package to help governments remove industrially produced trans fat from food supplies. The WHO target of full global elimination by the end of 2023 was not met, but by early 2025 about 3.9 billion people, just under half the world's population, lived in countries with best-practice trans fat policies. WHO describes trans fat elimination as a low-cost measure, particularly for low- and middle-income countries, and estimates that it addresses a meaningful share of global cardiovascular disease. Labeling and voluntary reformulation are considered less effective than mandatory limits or bans on partially hydrogenated oils.\n\nGuideline development\n\nMajor guideline bodies do not always agree on how to convert lipid values into action. The American College of Cardiology and American Heart Association have traditionally relied on risk estimation to determine statin intensity, while the European Society of Cardiology has more often used explicit LDL cholesterol thresholds and goals. The 2026 ACC/AHA guideline has reintroduced explicit LDL-C and non-HDL-C goals, narrowing this difference. Divergence also appears in pediatric screening, where US national bodies have favored universal testing and some other reviewers have emphasized the limits of evidence. These differences shape which people are screened, how early treatment begins, and how national health systems allocate resources."
    },
    {
      "heading": "History of Discovery",
      "text": "Early lipoprotein chemistry\n\nResearchers including Leonardo da Vinci and Rudolf Virchow observed the atheromatous disease for centuries and speculated about its cause, but the chemistry of blood lipids remained largely unmeasured until the mid-twentieth century. In 1949, John Gofman and colleagues used a new instrument, the analytical ultracentrifuge, to sort serum lipoproteins by how they floated. They identified two classes of cholesterol-rich particles, one corresponding to what is now called LDL and the other to HDL, and the names still in use date from this work.\n\nGofman's group then showed that cholesterol-fed rabbits and patients who had suffered heart attacks both displayed raised levels mainly in the LDL fraction. This made LDL, rather than total cholesterol, the lipoprotein most closely tied to arterial disease. The work was set against a population background: the Framingham Study, begun in 1946, had confirmed serum cholesterol levels as a major risk factor of atherosclerosis, which created demand for screening methods that could handle large numbers of samples. Ultracentrifugation was costly and slow for preparing material, and in their classic 1955 paper, Havel, Eder, and Bragdon devised a method to isolate large amounts of lipoproteins using a preparative ultracentrifuge, which allowed biochemical characterization of each class.\n\nIn 1967 Fredrickson and colleagues applied electrophoresis to the separation of lipoproteins and developed a classification of lipoprotein disorders, which was somewhat controversial but remains a reference. The authors expected that the biochemical phenotypes would eventually be shown to have a molecular genetic basis. That expectation was borne out only in part, a point developed in the classification sections.\n\nThe LDL receptor and familial hypercholesterolemia\n\nIn 1972 Michael S. Brown and Joseph L. Goldstein merged their two laboratories at the University of Texas Southwestern in Dallas, starting what is probably one of the longest running and most successful partnerships in science. Soon afterward their group reported the discovery of a cell surface receptor that binds cholesterol-carrying low-density lipoproteins. Their 1974 paper in the Proceedings of the National Academy of Sciences established that LDL attaches to this receptor, that the bound particle suppresses the activity of a key enzyme in cholesterol synthesis, and that a deficiency of the receptor underlies a major inherited cause of high cholesterol and premature atherosclerosis.\n\nThe clinical link came through patients with familial hypercholesterolemia. Brown and Goldstein found that the underlying mechanism of severe hereditary familial hypercholesterolemia is a complete or partial lack of functional LDL receptors. Their work also explained the feedback loop. In normal individuals, uptake of dietary cholesterol inhibits the cell's own synthesis of cholesterol, and as a consequence the number of LDL receptors on the cell surface is reduced. Fewer receptors leave more LDL circulating in the blood, which is the basis of the familial disorder. The 1985 Nobel Prize in Physiology or Medicine was awarded jointly to Michael S. Brown and Joseph L. Goldstein for their discoveries concerning the regulation of cholesterol metabolism.\n\nFrom fungal metabolites to statins\n\nThe biochemical background to statins lay in the work of Konrad Bloch, who began studying cholesterol metabolism in the 1940s and received a half share of the 1964 Nobel Prize in Physiology or Medicine for his work on describing the mechanism of cholesterol synthesis. Pharmaceutical efforts before statins relied on other strategies. The drugs used before this discovery to lower cholesterol did so by increasing the removal of cholesterol from the body or by inhibiting its absorption from food.\n\nAkira Endo, a biochemist at the Japanese company Sankyo, took a different route. Several pharmaceutical companies had failed to find a chemical which would inhibit HMG-CoA reductase, the enzyme that controls the rate-limiting step in cholesterol synthesis. Endo hoped that molds might yield such a substance. In August 1973, after testing 6,000 fungal broths, Endo discovered compactin (ML236B or mevastatin), an HMG-CoA reductase inhibitor, in the fermentation broth of the fungus Penicillium citrinum. In 1976, Endo published two papers reporting the discovery and characterization of compactin, the first statin. He noted that compactin resembled the enzyme's natural substrate and acted as a competitive inhibitor.\n\nClinical testing followed quickly. Yamamoto gave oral compactin to 11 patients with genetic forms of hypercholesterolemia, all of whom had been poorly responsive to available cholesterol-lowering drugs. The first commercially available statin was lovastatin, a close variant of the compactin molecule developed by Merck. Sources differ on the details of its origin: one account says the fungal source, <i>Aspergillus terreus</i>, was identified by Merck and Endo independently in 1979. Since lovastatin was commercialized, 10 statins were synthesized among which paravastatin was launched to the market by Sankyo in 1989. Endo's contribution was recognized with the 2008 Lasker–DeBakey Clinical Medical Research Award. Globally, statins are now prescribed to more than 200 million people.\n\nEvolution of guidelines\n\nEarly cholesterol guidance was largely population-based, framing high serum cholesterol as a public health problem for the general population. Through the late twentieth century, expert panels in the United States moved toward explicit LDL targets, a model that the 2001 National Cholesterol Education Program report exemplified. Later guidance shifted toward estimating an individual's cardiovascular risk and matching treatment intensity to that estimate, a change that became prominent with the 2013 ACC/AHA guideline. The balance between targets and intensity has continued to be debated in subsequent revisions."
    },
    {
      "heading": "Open Questions and Debates",
      "text": "The LDL hypothesis is among the best-supported ideas in cardiovascular medicine, but several questions remain open, and the answers would change how treatment targets, testing, and risk thresholds are set.\n\nWhether LDL cholesterol is causal for every event\n\nGenetic evidence is the strongest support for a causal role. In a Mendelian randomization study comparing variants in ACLY with statin-mimicking variants in HMGCR, the ACLY score was associated with a decrease of 17.7% in the risk of major cardiovascular events for each 10 mg per deciliter decrease in LDL cholesterol. The same study also questioned whether lowering LDL through a different enzyme pathway would produce the same clinical effect as a statin, a point the authors could not settle. Other drug-target analyses have produced discordant results. One study of acute myocardial infarction confirmed that LDL is causal, yet found that genetically proxied LDL reduction through HMGCR inhibition was not causally associated with AMI risk. Though LDL-C was found to have causal risk effects on AMI, genetically proxied lower LDL-C via HMGCR inhibition by statins were not causally associated with AMI risk.\n\nThe question of proportionality is also unresolved. Genetic studies suggest that lifelong lower LDL exposure produces a much larger reduction in events than the same magnitude of LDL lowering started late in life in randomized trials, but the benefit of lowering LDL at all ages between these two extremes is unknown. This gap bears on whether the lowest LDL levels, such as the very low targets discussed elsewhere in this article, produce benefit in proportion to the drop achieved.\n\nLipoprotein(a) and its clinical significance\n\nLipoprotein(a) is recognized as a causal-looking risk marker, but whether lowering it changes outcomes has not been established. In a secondary analysis of the FOURIER trial, evolocumab reduced Lp(a) by a median of 26.9% which appeared to translate into clinical benefit as greater Lp(a) reduction was associated with a greater reduction in cardiovascular risk. That observation came from a secondary analysis, not a dedicated test of Lp(a) lowering. The first large phase 3 test of a targeted agent has now reported. On September 4, 2026, Novartis announced that while pelacarsen lowered lipoprotein(a) [Lp(a)] levels, the trial failed to reduce the risk of major adverse cardiovascular events (MACE). Other agents remain in outcome trials; for example, the olpasiran outcomes trial has an estimated completion date of December 2026.\n\nThe debate extends to testing. The 2024 NLA Scientific Statement on the Use of Lp(a) in Clinical Practice and 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia recommend universal Lp(a) testing in all adults. Critics can reasonably ask whether measuring a value with no proven targeted treatment changes outcomes. Some clinicians have proposed a practical bridge: until completion of randomized clinical trials with selective Lp(a) lowering therapies, advocating a PCSK9 monoclonal antibody to lower LDL-C below 55 mg/dL in patients with high Lp(a) levels is one such approach, though this remains an expert recommendation rather than an established outcome-based standard.\n\nTriglycerides and residual risk\n\nEven when LDL is controlled, many patients remain at risk, and triglyceride-rich lipoproteins are a leading candidate explanation. Mendelian randomization analyses in the UK Biobank found that TRL/remnant-C was strongly and independently associated with CHD in a model adjusted for apolipoprotein B (apoB). A related analysis found higher per particle atherogenicity for triglyceride-rich lipoproteins/remnants than for low density lipoproteins. A recent review concluded that apolipoprotein B may be the principal driver of the risk linked to remnant lipoproteins.\n\nWhat remains uncertain is whether lowering triglycerides or remnant cholesterol with drugs yields clinical benefit comparable to the genetic estimates. Trials targeting these particles are less developed than LDL trials, and the apoB-versus-remnant-cholesterol question determines whether the best marker to target is apoB, non-HDL cholesterol, or a triglyceride-specific measure. Cardiovascular outcome data for triglyceride-lowering agents are still an active area of research.\n\nThresholds for borderline, intermediate, and older adults\n\nEven with a clear causal model, the cutoffs at which treatment begins for borderline and intermediate-risk adults are partly judgment. Risk equations, lifetime exposure, family history, and individual preferences all affect whether a given LDL value justifies drug therapy. Older adults raise a further problem: they are often underrepresented in trials, and the balance between benefit and harm shifts as life expectancy shortens. Professional bodies have not always reached the same conclusions on these points, and the differences in their recommendations reflect different weightings of the same uncertain evidence rather than disagreement about the basic biology of cholesterol."
    }
  ],
  "links": [
    "cholesterol",
    "atherosclerosis",
    "cardiovascular-disease",
    "diabetes-mellitus",
    "obesity",
    "hypothyroidism",
    "chronic-kidney-disease",
    "enzyme",
    "pancreas",
    "insulin-resistance",
    "type-two-diabetes",
    "gene",
    "genetics",
    "allele",
    "mutation",
    "pancreatitis",
    "coronary-artery-disease",
    "stroke",
    "randomized-controlled-trial",
    "c-reactive-protein",
    "monoclonal-antibody",
    "social-determinants-of-health",
    "public-health"
  ],
  "sources": [
    {
      "title": "Hyperlipidemia - an overview",
      "url": "https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/hyperlipidemia"
    },
    {
      "title": "Dyslipidemia vs Hyperlipidemia: Meaning and Treatment Plan",
      "url": "https://acibademinternational.com/blog/hyperlipidemia-vs-dyslipidemia-what-the-terms-mean-and-how-treatment-is-planned/"
    },
    {
      "title": "2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines",
      "url": "https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423"
    },
    {
      "title": "Dyslipidemia Management: ACC/AHA 2026 Guideline Summary",
      "url": "https://reference.medscape.com/cc2/p10/guideline-acc-aha-dyslipidemia-2026a1000cpb"
    },
    {
      "title": "Hyperlipidemia: Causes, diagnosis, and treatment",
      "url": "https://www.medicalnewstoday.com/articles/295385"
    },
    {
      "title": "Prioritizing Health",
      "url": "https://www.acc.org/latest-in-cardiology/articles/2026/07/01/01/prioritizing-health"
    },
    {
      "title": "Hyperlipidemia vs. Hypercholesterolemia: What's the Difference?",
      "url": "https://www.healthline.com/health/high-cholesterol/hyperlipidemia-vs-hypercholesterolemia"
    },
    {
      "title": "Dyslipidemia vs Hyperlipidemia: What's the Difference?",
      "url": "https://resources.healthgrades.com/right-care/cholesterol/dyslipidemia-vs-hyperlipidemia"
    },
    {
      "title": "Dyslipidemia: Symptoms, Treatment, and More",
      "url": "https://www.healthline.com/health/dyslipidemia"
    },
    {
      "title": "Hyperlipidemia Causes, Symptoms, and Treatments",
      "url": "https://www.upmc.com/services/heart-vascular/conditions/hyperlipidemia"
    },
    {
      "title": "Selective Hepatic Insulin Resistance, VLDL Overproduction, and Hypertriglyceridemia",
      "url": "https://www.ahajournals.org/doi/10.1161/atvbaha.111.241463"
    },
    {
      "title": "Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease",
      "url": "https://link.springer.com/article/10.1007/s00535-013-0758-5"
    },
    {
      "title": "Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion",
      "url": "https://nutritionandmetabolism.biomedcentral.com/articles/10.1186/1743-7075-7-35"
    },
    {
      "title": "JCI - SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver",
      "url": "https://www.jci.org/articles/view/15593"
    },
    {
      "title": "Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics",
      "url": "https://www.nature.com/articles/s41392-022-01125-5"
    },
    {
      "title": "The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor: Cell",
      "url": "https://www.cell.com/fulltext/S0092-8674(00)80213-5"
    },
    {
      "title": "Genes and proteins controlling cholesterol synthesis",
      "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6333172"
    },
    {
      "title": "Recent discoveries concerning regulation of Cholesterol ...",
      "url": "https://fse.studenttheses.ub.rug.nl/16411/1/Marijn_Riemsma_Final_Version_S_1.pdf"
    },
    {
      "title": "The role of ANGPTL3 in controlling lipoprotein metabolism",
      "url": "https://link.springer.com/article/10.1007/s12020-015-0838-9"
    },
    {
      "title": "Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8",
      "url": "https://journals.physiology.org/doi/full/10.1152/ajpendo.00195.2021"
    },
    {
      "title": "ANGPTL3 deficiency impairs lipoprotein production and produces adaptive changes in hepatic lipid metabolism",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10875267/"
    },
    {
      "title": "Angiopoietin-like 3 in lipoprotein metabolism",
      "url": "https://www.nature.com/articles/nrendo.2017.119"
    },
    {
      "title": "Hyperlipidemia",
      "url": "https://en.wikipedia.org/wiki/Hyperlipidemia"
    },
    {
      "title": "Hyperlipidemia: Symptoms and Causes",
      "url": "https://www.tgh.org/institutes-and-services/conditions/hyperlipidemia"
    },
    {
      "title": "Hyperlipidaemia",
      "url": "https://geekymedics.com/hyperlipidaemia/"
    },
    {
      "title": "Secondary Causes of Hyperlipidemia: Diet, Metabolic Disorders, and More",
      "url": "https://www.healthcentral.com/condition/high-cholesterol/secondary-causes-of-hyperlipidemia"
    },
    {
      "title": "Familial Combined Hyperlipidemia - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37276316/"
    },
    {
      "title": "Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0021915021014726"
    },
    {
      "title": "Polygenic Hypercholesterolemia - StatPearls - NCBI Bookshelf",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK559143/"
    },
    {
      "title": "Pulsenotes",
      "url": "https://app.pulsenotes.com/specialities/biochemistry/notes/hyperlipidaemia"
    },
    {
      "title": "Familial combined hyperlipidaemia/polygenic mixed hyperlipidaemia - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34006353/"
    },
    {
      "title": "Familial Combined Hyperlipidemia: Myth or Reality?",
      "url": "https://link.springer.com/article/10.1007/s11883-025-01289-9"
    },
    {
      "title": "Fredrickson’s Classification of the Hyperlipoproteinaemias",
      "url": "https://link.springer.com/chapter/10.1007/978-90-481-8875-8_7"
    },
    {
      "title": "Cyclic ether DGAT1 inhibitorscyclic ether DGAT1 inhibitors",
      "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9108956"
    },
    {
      "title": "Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations",
      "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9593333"
    },
    {
      "title": "Modulation of apolipoprotein CIII (ApoCIII) expression",
      "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9157082"
    },
    {
      "title": "Oligosaccharide compositions and methods of use",
      "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12508274"
    },
    {
      "title": "MODERN-DAY PREVALENCE OF THE FREDRICKSON-LEVY-LEES DYSLIPIDEMIAS: MORE COMMON THAN YOU THINK",
      "url": "https://www.jacc.org/doi/10.1016/S0735-1097(18)32313-1"
    },
    {
      "title": "Dr D.S. Fredrickson: Founding father of the field of lipidology",
      "url": "https://bcmj.org/articles/dr-ds-fredrickson-founding-father-field-lipidology"
    },
    {
      "title": "A new phenotypic classification system for dyslipidemias based on the standard lipid panel",
      "url": "https://link.springer.com/article/10.1186/s12944-021-01585-8"
    },
    {
      "title": "WHO/Fredrickson classification of primary hyperlipidaemias",
      "url": "https://gpnotebook.com/pages/cardiovascular-medicine/whofredrickson-classification-of-primary-hyperlipidaemias"
    },
    {
      "title": "Fredrickson's classification of phenotypes 8",
      "url": "https://www.researchgate.net/figure/Fredricksons-classification-of-phenotypes-8_tbl2_372689054"
    },
    {
      "title": "Combined Lipid Disturbances: More Than the Sum of Their Parts?",
      "url": "https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.124.324793"
    },
    {
      "title": "Fredrickson classification - Altmeyers Encyclopedia - Department Internal medicine",
      "url": "https://www.altmeyers.org/en/internal-medicine/fredrickson-classification-142187"
    },
    {
      "title": "Genetic Architecture And Clinical Outcomes Of The Fredrickson-Levy-Lees Dyslipoproteinemias",
      "url": "https://www.medrxiv.org/content/10.1101/2022.05.26.22275391.full.pdf"
    },
    {
      "title": "Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: findings from the Very Large Database of Lipids and National Health and Nutrition Examination Survey",
      "url": "https://www.archivesofmedicalscience.com/Modern-prevalence-of-the-Fredrickson-Levy-Lees-r-ndyslipidemias-findings-from-the,110467,0,2.html"
    },
    {
      "title": "The genetics and screening of familial hypercholesterolaemia",
      "url": "https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-016-0256-1"
    },
    {
      "title": "Familial hypercholesterolemia: MedlinePlus Genetics",
      "url": "https://medlineplus.gov/genetics/condition/familial-hypercholesterolemia/"
    },
    {
      "title": "Genetic testing for familial hypercholesterolemia - PMC - NIH",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10932851/"
    },
    {
      "title": "Genetic Architecture of Familial Hypercholesterolaemia - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28405938/"
    },
    {
      "title": "Familial hypercholesterolemia: Detect, treat, and ask about family",
      "url": "https://www.ccjm.org/content/87/2/109"
    },
    {
      "title": "Familial Combined Hyperlipidemia - StatPearls - NCBI Bookshelf",
      "url": "https://www.ncbi.nlm.nih.gov/sites/books/NBK592399/"
    },
    {
      "title": "Genetics and Dyslipidemia - Endotext - NCBI Bookshelf - NIH",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK395584/"
    },
    {
      "title": "Combined Hyperlipidemia - an overview",
      "url": "https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/combined-hyperlipidemia"
    },
    {
      "title": "Dysbetalipoproteinemia - StatPearls - NCBI Bookshelf - NIH",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK567738/"
    },
    {
      "title": "Dysbetalipoproteinemia (Type 3 Hyperlipoproteinemia) - Endotext - NCBI Bookshelf",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK611310/"
    },
    {
      "title": "Familial Dysbetalipoproteinemia - an overview",
      "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/familial-dysbetalipoproteinemia"
    },
    {
      "title": "Hyperlipoproteinemia Type 3 - an overview",
      "url": "https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/hyperlipoproteinemia-type-3"
    },
    {
      "title": "Endocrine diseases as causes of secondary hyperlipidemia",
      "url": "https://journals.viamedica.pl/endokrynologia_polska/article/view/65213"
    },
    {
      "title": "Hypertriglyceridemia: Background, Etiology, Pathophysiology",
      "url": "https://emedicine.medscape.com/article/126568-overview"
    },
    {
      "title": "Secondary dyslipidemia",
      "url": "https://www.slideshare.net/slideshow/secondary-dyslipidemia/91675406"
    },
    {
      "title": "Hyperlipidemia - StatPearls - NCBI Bookshelf - NIH",
      "url": "https://www.ncbi.nlm.nih.gov/sites/books/NBK559182/"
    },
    {
      "title": "Drug-Induced Lipid Changes: A Review of the Unintended Effects of Some Commonly Used Drugs on Serum Lipid Levels",
      "url": "https://www.researchgate.net/publication/11970416_Drug-Induced_Lipid_Changes_A_Review_of_the_Unintended_Effects_of_Some_Commonly_Used_Drugs_on_Serum_Lipid_Levels"
    },
    {
      "title": "Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/11368251/"
    },
    {
      "title": "Hyperlipidaemia (secondary causes of)",
      "url": "https://gpnotebook.com/pages/cardiovascular-medicine/hyperlipidaemia-secondary-causes-of"
    },
    {
      "title": "[Secondary disorders of lipid metabolism, metabolic syndrome and familial combined hyperlipidemia] - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/8650933/"
    },
    {
      "title": "Dyslipidemia - Endocrinology - Merck Manual Professional Edition",
      "url": "https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/lipid-disorders/dyslipidemia"
    },
    {
      "title": "Clinical Feature: Dyslipidemia & Antipsychotic Medications: Who is Monitoring the Lipids?",
      "url": "https://www.lipid.org/node/1768"
    },
    {
      "title": "Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis",
      "url": "https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2580722"
    },
    {
      "title": "Rates of acute pancreatitis and cardiovascular events among adults with severe or extreme hypertriglyceridemia in US clinical practice",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305886/"
    },
    {
      "title": "Prevention and treatment of hypertriglyceridemia-mediated acute pancreatitis: A narrative review - European Journal of Internal Medicine",
      "url": "https://www.ejinme.com/article/S0953-6205(25)00525-4/fulltext"
    },
    {
      "title": "Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline",
      "url": "https://academic.oup.com/jcem/article/97/9/2969/2536709"
    },
    {
      "title": "Familial Hypercholesterolemia: Background, Etiology, Pathophysiology",
      "url": "https://emedicine.medscape.com/article/121298-overview"
    },
    {
      "title": "Xanthomas Clinical Presentation: History, Physical Examination, Complications",
      "url": "https://emedicine.medscape.com/article/1103971-clinical"
    },
    {
      "title": "The value of physical signs in identifying patients with familial hypercholesterolemia in the era of genetic testing - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/pii/S0914508720302379"
    },
    {
      "title": "Xanthomas and Xanthelasmas in Older Adults",
      "url": "https://link.springer.com/rwe/10.1007/978-3-031-53888-9_37-1"
    },
    {
      "title": "Successful Resolution of Eruptive Xanthomas in Severe Hypertriglyceridemia With Plasmapheresis",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927605/"
    },
    {
      "title": "Corneal Arcus, Xanthomas, and Finger Deformities in a Young Woman With Homozygous Familial Hypercholesterolemia - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12507493/"
    },
    {
      "title": "Familial homozygous hypercholesterolemia with arcus cornea and xanthomas: A rare but serious entity - Chamli - 2023 - Clinical Case Reports - Wiley Online Library",
      "url": "https://onlinelibrary.wiley.com/doi/full/10.1002/ccr3.7024"
    },
    {
      "title": "Corneal arcus as the first presentation of hypercholesterolemia in children - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0031393913002850"
    },
    {
      "title": "Hyperlipidemia Symptoms: Signs, Warning Symptoms & Diagnosis",
      "url": "https://www.policybazaar.com/health-wellness/diseases/hyperlipidemia/symptoms/"
    },
    {
      "title": "A Case of Recurrent Acute Pancreatitis Secondary to Hypertriglyceridemia",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113948/"
    },
    {
      "title": "2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines",
      "url": "https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016"
    },
    {
      "title": "Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/pii/S073510971301098X"
    },
    {
      "title": "Lipid Profiling in Obesity: The Limitations of the Friedewald Equation - The American Journal of Medicine",
      "url": "https://www.amjmed.com/article/S0002-9343(24)00581-3/fulltext"
    },
    {
      "title": "Comparative Evaluation of 24 LDL-C Estimation Equations Against Direct Assays in Two Independent Cohorts",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468580/"
    },
    {
      "title": "Direct versus calculated LDL cholesterol: Insights from the Friedewald, Martin–Hopkins, and Sampson approaches in the Indian population",
      "url": "https://www.reccardioclinics.org/en-direct-versus-calculated-ldl-cholesterol-avance-S2605153225001499"
    },
    {
      "title": "LDL Calculator: Friedewald vs NIH Equation (Calculated LDL)",
      "url": "https://prospyrmed.com/tools/ldl-calculator"
    },
    {
      "title": "Apolipoprotein B in cardiovascular risk assessment",
      "url": "https://www.cmaj.ca/content/195/33/E1124"
    },
    {
      "title": "2026 cholesterol guidelines recommend earlier treatment",
      "url": "https://www.empirical.health/blog/cholesterol-guidelines-heart-health/"
    },
    {
      "title": "2026 ACC/AHA dyslipidemia guideline update: Key recommendations for laboratory reporting and clinical interpretation",
      "url": "https://www.labcorp.com/education-events/articles/2026-accaha-dyslipidemia-guideline-update"
    },
    {
      "title": "LDL Calculator: Friedewald Equation",
      "url": "https://acibademinternational.com/ldl-calculator/"
    },
    {
      "title": "AHA PREVENT Cardiovascular Risk Calculator",
      "url": "https://heartcare.sydney/prevent-risk-calculator/"
    },
    {
      "title": "CVD Risk Estimator + - Mobile and Web Apps",
      "url": "https://tools.acc.org/cvd-risk-estimator-plus/"
    },
    {
      "title": "What PREVENT can tell you about heart disease risk",
      "url": "https://www.heart.org/en/news/2026/08/31/what-prevent-can-tell-you-about-heart-disease-risk"
    },
    {
      "title": "Systematic examination of the PREVENT equations for cardiovascular disease risk - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/pii/S2666667726000966"
    },
    {
      "title": "AHA PREVENT CVD Risk Calculator",
      "url": "https://endocrine.plus/patient-resources/calc-prevent.html"
    },
    {
      "title": "PREVENT Equations: A New Era in Cardiovascular Disease Risk Assessment",
      "url": "https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.123.010763"
    },
    {
      "title": "Development and Validation of the American Heart Association’s PREVENT Equations",
      "url": "https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067626"
    },
    {
      "title": "2026 Dyslipidemia Guideline-at-a-Glance",
      "url": "https://www.jacc.org/doi/10.1016/j.jacc.2026.02.4872"
    },
    {
      "title": "2026 ACC/AHA/Multisociety Dyslipidemia Guideline Released",
      "url": "https://www.lipid.org/nla/2026-accahamultisociety-dyslipidemia-guideline-released"
    },
    {
      "title": "ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia - American College of Cardiology",
      "url": "https://www.acc.org/latest-in-cardiology/journal-scans/2026/03/13/15/20/acc-aha-release-new-clinical-guideline-for-managing-dyslipidemia"
    },
    {
      "title": "Coronary artery calcium scoring: An adjunct to risk stratification, not a replacement for it - The American Journal of Medicine",
      "url": "https://www.amjmed.com/article/S0002-9343(26)00208-1/fulltext"
    },
    {
      "title": "What the 2026 Dyslipidemia Guidelines Mean for Your Patients and Your Practice",
      "url": "https://www.cardiometabolichealth.org/what-the-2026-dyslipidemia-guidelines-mean-for-your-patients-and-your-practice/"
    },
    {
      "title": "New Cholesterol Guidelines 2026: What Changed",
      "url": "https://themetabolicjournal.com/guidelines/new-cholesterol-guidelines-2026"
    },
    {
      "title": "The 2026 ACC/AHA Dyslipidemia Guideline: A Critical and Transatlantic Perspective on Personalized Lipid Management",
      "url": "https://doi.org/10.3390/life16091470"
    },
    {
      "title": "ACC and AHA Release Updated 2026 Dyslipidemia Management Guidelines",
      "url": "https://www.thecardiologyadvisor.com/news/acc-aha-2026-dyslipidemia-guidelines-update/"
    },
    {
      "title": "2026 ACC/AHA Cholesterol Guidelines: Key Updates",
      "url": "https://heartcare.sydney/acc-aha-2026-dyslipidemia-guidelines/"
    },
    {
      "title": "Implications of the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline for Lipid Management in Vascular Disease - American College of Cardiology",
      "url": "https://www.acc.org/latest-in-cardiology/articles/2026/06/15/14/16/implications-of-the-2026-multisociety-dyslipidemia-guideline"
    },
    {
      "title": "Guideline on the Management of Dyslipidemia - Professional Heart Daily",
      "url": "https://professional.heart.org/en/science-news/2026-guideline-on-the-management-of-dyslipidemia/top-things-to-know"
    },
    {
      "title": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6233651"
    },
    {
      "title": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2988224/"
    },
    {
      "title": "Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials: A meta-analysis - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/pii/S1933287426000395"
    },
    {
      "title": "ACC/AHA Management of Dyslipidemia Guideline Summary - Guideline Central",
      "url": "https://www.guidelinecentral.com/guideline/5099440/"
    },
    {
      "title": "Extent of Low-density Lipoprotein Cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: A Systematic Review and Meta-analysis - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9812424/"
    },
    {
      "title": "Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials - The Lancet",
      "url": "https://www.thelancet.com/article/S0140-6736(10)61350-5/fulltext"
    },
    {
      "title": "The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials - The Lancet",
      "url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60367-5/fulltext"
    },
    {
      "title": "What are key updates from the 2026 ACC / AHA / AACVPR / ABC / ACPM / ADA / AGS / APhA / ASPC / NLA / PCNA guideline on dyslipidemia management?",
      "url": "https://dig.pharmacy.uic.edu/faqs/2026-2/may-2026-faqs/what-are-key-updates-from-the-2026-acc-aha-aacvpr-abc-acpm-ada-ags-apha-aspc-nla-pcna-guideline-on-dyslipidemia-management/"
    },
    {
      "title": "2026 ACC/AHA Dyslipidemia Guidelines — Quick Reference — Satti MD",
      "url": "https://sattimd.com/guidelines/acc-dyslipidemia-2026.html"
    },
    {
      "title": "Triglyceride Lowering Drugs - Endotext - NCBI Bookshelf - NIH",
      "url": "https://www.ncbi.nlm.nih.gov/sites/books/NBK425699/"
    },
    {
      "title": "Hypertriglyceridemia and omega-3 fatty acids: Their often overlooked role in cardiovascular disease prevention - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/pii/S0939475317302685"
    },
    {
      "title": "Omega-3 fatty acids for cardiovascular event lowering",
      "url": "https://academic.oup.com/eurjpc/article/31/8/1005/7505348"
    },
    {
      "title": "Omega-3 fatty acids for cardiovascular event lowering",
      "url": "https://academic.oup.com/eurjpc/article-pdf/31/8/1005/58009495/zwae003.pdf"
    },
    {
      "title": "Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S1933287416300423"
    },
    {
      "title": "New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330561/"
    },
    {
      "title": "Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia",
      "url": "https://www.esperion.com/news-releases/news-release-details/esperions-bempedoic-acid-receives-multiple-class-1"
    },
    {
      "title": "2026 ACC/AHA Guideline for the Management of Dyslipidemia - MedScriptum",
      "url": "https://medscriptum.org/en/2026-acc-aha-guideline-for-the-management-of-dyslipidemia/"
    },
    {
      "title": "Effects of lifestyle interventions on high-density lipoprotein cholesterol levels - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S1933287407000104"
    },
    {
      "title": "Long Term Effects of a Lifestyle Intervention on Weight and Cardiovascular Risk Factors in Individuals with Type 2 Diabetes: Four Year Results of the Look AHEAD Trial - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3084497/"
    },
    {
      "title": "Diet and Exercise in the Management of Hyperlipidemia",
      "url": "https://www.aafp.org/afp/2010/0501/p1097"
    },
    {
      "title": "ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol - American College of Cardiology",
      "url": "https://www.acc.org/about-acc/press-releases/2026/03/13/18/01/accaha-issue-updated-guideline-for-managing-lipids-cholesterol"
    },
    {
      "title": "Comparison of effects of diet versus exercise weight loss regimens on LDL and HDL particle size in obese adults",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150311/"
    },
    {
      "title": "Hypertriglyceridemia Treatment & Management: Approach Considerations, Pharmacologic Therapy, Adult Treatment Panel Guidelines",
      "url": "https://emedicine.medscape.com/article/126568-treatment"
    },
    {
      "title": "Primary Prevention Statin Implications of the 2026 Dyslipidemia Guideline - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13386295/"
    },
    {
      "title": "Dyslipidemia in Pregnancy: How to Deal - Indian Journal of Cardiovascular Disease in Women",
      "url": "https://ijcdw.org/dyslipidemia-in-pregnancy-how-to-deal/"
    },
    {
      "title": "Management of dyslipidemia in adults. A consensus ...",
      "url": "https://www.sfdiabete.org/sites/www.sfdiabete.org/files/files/ressources/management_of_dyslipidemia_in_adults._guidelines_sfe_sfd_nsfa_sfc_2026.pdf"
    },
    {
      "title": "Lipid-lowering therapy for primary prevention of cardiovascular disease in adults aged 75 years and older: a narrative review - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13147402/"
    },
    {
      "title": "Discontinuing Statins for Primary Prevention in Older Adults",
      "url": "https://www.aafp.org/afp/afp-community-blog/discontinuing-statins-for-primary-prevention-in-older-adults"
    },
    {
      "title": "Recommendation: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication",
      "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/statin-use-in-adults-preventive-medication"
    },
    {
      "title": "Dyslipidaemia management in pregnant patients: a 2024 update",
      "url": "https://academic.oup.com/ehjopen/article/4/3/oeae032/7658837"
    },
    {
      "title": "[Statin-induced muscle symptoms] - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41251244/"
    },
    {
      "title": "Lancet Study Highlights \"Nocebo\" Effect of Statins",
      "url": "https://www.ajmc.com/view/no-rise-in-side-effects-from-statins-when-patients-dont-know-theyre-taking-them-lancet-finds"
    },
    {
      "title": "Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration",
      "url": "https://www.tctmd.com/news/only-very-small-risk-muscle-symptoms-statins-ctt-collaboration"
    },
    {
      "title": "Statin-Associated Muscle Symptoms and Myotoxicity: A Clinically Oriented Narrative Review with a Practical Prevention, Evaluation, and Management Algorithm",
      "url": "https://www.mdpi.com/1648-9144/62/6/1134"
    },
    {
      "title": "SAMSON trial - BHF",
      "url": "https://www.bhf.org.uk/what-we-do/our-research/impact-of-clinical-trials/prevention/samson-trial"
    },
    {
      "title": "MUscle Side-Effects of Atorvastatin in Coronary Patients (MUSE) -Follow-up Study",
      "url": "https://clinicaltrials.gov/study/NCT04453735"
    },
    {
      "title": "Statin use and risk of new-onset diabetes: A meta-analysis of observational studies - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0939475317300431"
    },
    {
      "title": "Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223121/"
    },
    {
      "title": "Statins and new-onset diabetes in primary prevention setting: an updated meta-analysis stratified by baseline diabetes risk",
      "url": "https://link.springer.com/article/10.1007/s00592-023-02205-w"
    },
    {
      "title": "Risk of new-onset diabetes associated with statin use - Robert D Beckett, Sarah M Schepers, Sarah K Gordon, 2015",
      "url": "https://journals.sagepub.com/doi/10.1177/2050312115605518"
    },
    {
      "title": "Global prevalence of dyslipidemias in the general adult population: a systematic review and meta-analysis",
      "url": "https://link.springer.com/article/10.1186/s41043-025-01054-3"
    },
    {
      "title": "Hypercholesterolemia - an overview",
      "url": "https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/hypercholesterolemia"
    },
    {
      "title": "WORLD HEART FEDERATION ROADMAP FOR CHOLESTEROL",
      "url": "https://world-heart-federation.org/wp-content/uploads/WHF-Cholesterol-Roadmap-Summary-Document.pdf"
    },
    {
      "title": "Global prevalence of dyslipidaemia in adult populations: a systematic review protocol - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8647546/"
    },
    {
      "title": "Prevalence of Familial Hypercholesterolemia in Pakistan: A Pooled Analysis of 1.5 Million Individuals and Comparison with Other Countries of the Region",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11908433/"
    },
    {
      "title": "Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease",
      "url": "https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.044795"
    },
    {
      "title": "Prevalence and factors associated with possible cases of familial hypercholesterolemia in Brazilian adults: a cross-sectional study",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665423/"
    },
    {
      "title": "Familial hypercholesterolaemia in UK primary care: a Clinical Practice Research Datalink study of an under-recognised condition",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10877619/"
    },
    {
      "title": "A mixed methods study of the awareness and management of familial hypercholesterolaemia in Irish general practice",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596980/"
    },
    {
      "title": "Lipid-Lowering Treatment in Familial Hypercholesterolaemia, 1996–2021: A Nationwide Study - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/pii/S2666776226001213"
    },
    {
      "title": "Low Rates of Both Lipid-Lowering Therapy Use and Achievement of Low-Density Lipoprotein Cholesterol Targets in Individuals at High-Risk for Cardiovascular Disease across Europe",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333116/"
    },
    {
      "title": "Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study - The Lancet Regional Health",
      "url": "https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(23)00043-1/fulltext"
    },
    {
      "title": "Lipid-Lowering Treatment Gaps in Patients after Acute Myocardial Infarction: Using Global Database TriNetX",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11434399/"
    },
    {
      "title": "Lipid-Lowering Therapy in the U.S. Adults Before and After the COVID-19 Pandemic",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12205634/"
    },
    {
      "title": "Factors explaining the gender disparity in lipid-lowering treatment goal attainment rate in Chinese patients with statin therapy",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3697899/"
    },
    {
      "title": "Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants - The Lancet Diabetes & Endocrinology",
      "url": "https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30388-2/abstract"
    },
    {
      "title": "Pediatric Lipid Screening - Family Heart Foundation",
      "url": "https://familyheart.org/pediatric-lipid-screening"
    },
    {
      "title": "Universal Cholesterol Screening Referral Guidelines",
      "url": "https://www.childrensnational.org/for-healthcare-professionals/refer-a-patient/referral-guidelines/universal-cholesterol-screening-guidelines"
    },
    {
      "title": "Universal Screening for Familial Hypercholesterolemia in Preschool Children and Their Families in Slovenia (FH-FAMILIES)—A Protocol for a Study of Four-Stage Screening Program",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12653880/"
    },
    {
      "title": "Screening for Familial Hypercholesterolemia in Children: What Can We Learn From Adult Screening Programs? - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4934628/"
    },
    {
      "title": "Lipid Luminations: The Controversy Over Universal Cholesterol Screening for Children",
      "url": "https://www.lipid.org/communications/lipidspin/2012FALL19"
    },
    {
      "title": "Universal Pediatric Cholesterol Screening: The Time Has Come! - The Journal of Pediatrics",
      "url": "https://www.jpeds.com/article/S0022-3476(24)00031-3/fulltext"
    },
    {
      "title": "LEAD Pediatric Cholesterol Screening Initiative - Family Heart Foundation",
      "url": "https://familyheart.org/lead-pediatric-cholesterol-screening-initiative"
    },
    {
      "title": "Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK",
      "url": "https://academic.oup.com/eurheartj/article/38/23/1832/3104460"
    },
    {
      "title": "Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review",
      "url": "https://link.springer.com/article/10.1007/s40273-023-01347-7"
    },
    {
      "title": "Synthesized economic evidence on the cost-effectiveness of screening familial hypercholesterolemia",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11425997/"
    },
    {
      "title": "Cost-effectiveness of cascade genetic testing for familial hypercholesterolemia in the United States: A simulation analysis - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/pii/S2666667721001008"
    },
    {
      "title": "Cost-effectiveness of alternative cascade screening strategies for familial hypercholesterolemia with realistic cascade screening acceptance rates and use of novel treatment - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0021915025013140"
    },
    {
      "title": "Trans Fat Elimination Strategies at Resolve to Save Lives",
      "url": "https://resolvetosavelives.org/healthier-food/trans-fat-elimination/"
    },
    {
      "title": "Trans fat",
      "url": "https://www.who.int/news-room/fact-sheets/detail/trans-fat"
    },
    {
      "title": "Ending Trans Fat—The First-Ever Global Elimination Program for a Noncommunicable Disease Risk Factor: JACC International",
      "url": "https://www.jacc.org/doi/10.1016/j.jacc.2024.04.067"
    },
    {
      "title": "REPLACE trans fat: policies to eliminate industrially produced trans fat",
      "url": "https://www.who.int/publications/i/item/WHO-NMH-NHD-18.5"
    },
    {
      "title": "WHO awards countries for progress in eliminating industrially produced trans fats for first time",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11115398/"
    },
    {
      "title": "Akira Endo: Father of Statins",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439472/"
    },
    {
      "title": "How the JCI’s most-cited paper sparked the field of lipoprotein research",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10866646/"
    },
    {
      "title": "[From Fredrickson's classification of phenotypes--lipoprotein patterns--to genotype comprehension] - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/16207455/"
    },
    {
      "title": "A Century of Milestones and Breakthroughs Related to Low and High Density Lipoproteins - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10760802/"
    },
    {
      "title": "Joseph Goldstein and Michael Brown",
      "url": "https://www.ahajournals.org/doi/10.1161/res.0b013e3181dcab4d"
    },
    {
      "title": "The Nobel Prize in Physiology or Medicine 1985 - Press release - NobelPrize.org",
      "url": "https://www.nobelprize.org/prizes/medicine/1985/press-release/"
    },
    {
      "title": "Endo, Akira - Science Heroes",
      "url": "http://www.scienceheroes.com/endo-statins"
    },
    {
      "title": "On the History of Statins",
      "url": "https://www.clinicalcorrelations.org/2019/01/11/on-the-history-of-statins/"
    },
    {
      "title": "Statins for lowering LDL and decreasing heart attacks - Lasker Foundation",
      "url": "https://laskerfoundation.org/winners/statins-for-lowering-ldl-and-decreasing-heart-attacks/"
    },
    {
      "title": "Akira Endo - The Lancet",
      "url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01497-1/fulltext"
    },
    {
      "title": "Discovery and Development of Statins - Akira Endo, 2017",
      "url": "https://journals.sagepub.com/doi/abs/10.1177/1934578X1701200801"
    },
    {
      "title": "Discovery of the cellular and molecular basis of cholesterol control",
      "url": "https://www.pnas.org/doi/10.1073/pnas.1312967110"
    },
    {
      "title": "In memoriam: Akira Endo",
      "url": "https://academic.oup.com/eurheartj/article/45/35/3199/7739013"
    },
    {
      "title": "Mendelian Randomization Study of ACLY and Cardiovascular Disease",
      "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1806747"
    },
    {
      "title": "Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study",
      "url": "https://link.springer.com/article/10.1186/s12944-024-02133-w"
    },
    {
      "title": "A NATUrally Randomized trial Evaluating a vaccine-like strategy to lower LDL by inhibiting PCSK9 on the lifetime risk of major cardiovascular events (NATURE-PCSK9)",
      "url": "https://www.medrxiv.org/content/10.1101/2024.06.30.24309740.full.pdf"
    },
    {
      "title": "Lipoprotein(a) at a “Tipping Point”: case to move to universal screening - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/pii/S2666667725003496"
    },
    {
      "title": "Top Line Results from the Phase 3 Lp(a)HORIZON Trial - National Lipid Association",
      "url": "https://www.lipid.org/resource/top-line-results-from-the-phase-3-lpahorizon-trial/"
    },
    {
      "title": "Four Lp(a)-lowering drugs in trials reduce levels by up to 94%.",
      "url": "https://www.empirical.health/blog/lpa-lowering-medications/"
    },
    {
      "title": "Lipoprotein(a) and the Risk for Recurrent Ischemic Stroke Events",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11198620/"
    },
    {
      "title": "Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study",
      "url": "https://academic.oup.com/eurheartj/article/44/39/4186/7207673"
    },
    {
      "title": "Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies",
      "url": "https://link.springer.com/article/10.1007/s11886-025-02337-1"
    },
    {
      "title": "Independent Causal Effect of Remnant Cholesterol on Atherosclerotic Cardiovascular Outcomes: A Mendelian Randomization Study",
      "url": "https://www.ahajournals.org/doi/10.1161/ATVBAHA.123.319297"
    },
    {
      "title": "Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12764623/"
    }
  ],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}